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ABSTRACT
An estimated 34 million people worldwide are infected with human
immunodeficiency virus (HIV). Understanding how the immune system reacts to HIV
infection and why normal antiviral defenses are insufficient to fight infection is a key step
towards creating better therapies. Several interferon-induced proteins, such as the
tripartite motif protein TRIM22, are capable of restricting HIV-1 replication in vitro;
however the contribution of these antiviral factors to HIV-1 pathogenesis is unclear.
Previous studies have observed that single nucleotide polymorphisms (SNPs) can
dramatically impact the actions of these proteins and influence the severity of HIV-1
infection. While numerous SNPs have been reported in the trim22 gene, no study has
addressed how these may affect TRIM22 functions. Here we used U2OS cells to provide
the first direct comparison of two TRIM22 isoforms. Through confocal microscopy we
observed these isoforms to exhibit different patterns of localization, was dependent on the
TRIM22 B30.2 domain. In vitro studies revealed that both isoforms restricted release of
infectious HIV-1 particles, though to different extents. Furthermore, both isoforms
restricted transcription from the HIV-1 and cytomegalovirus promoters to varying
degrees, as determined by qRT-PCR analysis. Collectively, these data suggest that
TRIM22 antiviral activity is variable between isoforms, and that SNPs may alter its
biological characteristics.

KEYWORDS
Human immunodeficiency virus, TRIM22, tripartite motif proteins, antiviral, innate
immunity, interferon, restriction factor, single nucleotide polymorphism

iii

DEDICATION
I dedicate this thesis to my father, Peter, and my step-mother, Sharon. Your
unwavering love and support has helped guide me to where I am today, and your
encouragement to always pursue my dreams means the world to me. Thank you for
always believing in me.

iv

ACKNOWLEDGEMENTS
First and foremost, I must thank my supervisor Dr. Stephen Barr for giving me the
opportunity to work in his laboratory. Your patience and good nature are unrivalled, and
you were an inspiration for my work. Your guidance has been invaluable to my
education, and I am fortunate to have had you as my mentor, as I will remember your
lessons throughout the rest of my journeys. You believed in me and provided me a
chance to fulfill a dream, for which I am forever grateful.
I would also like to thank my Advisory Committee members, Dr. Joe Mymryk,
Dr. Rodney DeKoter, and Dr. Joaquín Madrenas, for their unique input, thoughtful
insight, and constructive criticism, all of which have benefited my project.
Finally, I am indebted to the faculty, staff, and my colleagues within the MNI
department. To anyone who loaned me a reagent, helped with an experiment, provided
advice or an open ear – and even those who were a welcome distraction during late nights
in the lab, thank you for everything. You have made my time here memorable.

v

TABLE OF CONTENTS
CERTIFICATE OF EXAMINATION ............................................................................... ii
ABSTRACT ....................................................................................................................... iii
KEYWORDS ..................................................................................................................... iii
DEDICATION ....................................................................................................................iv
ACKNOWLEDGEMENTS .................................................................................................v
LIST OF FIGURES ......................................................................................................... viii
LIST OF TABLES ..............................................................................................................ix
LIST OF APPENDICES ......................................................................................................x
LIST OF ABBREVIATIONS .............................................................................................xi
CHAPTER 1: INTRODUCTION ........................................................................................ 1
1.1

Human Immunodeficiency Virus Type 1 .............................................................. 1

1.2

The interferon response ......................................................................................... 8

1.3

HIV-1 restriction factors ...................................................................................... 13

1.3.1

APOBEC3 ....................................................................................................13

1.3.2

Tetherin .........................................................................................................13

1.4

Tripartite Motif (TRIM) Proteins ........................................................................14

1.4.1

TRIM5α ........................................................................................................15

1.4.2

TRIM22 ........................................................................................................18

1.5

TRIM22 inhibits HIV-1 Replication ...................................................................19

1.6

Rationale for studying innate viral restriction factors .........................................22

1.7

Hypothesis and specific aims...............................................................................26

CHAPTER 2: MATERIALS AND METHODS ............................................................... 27
2.1

Cells and cell lines ............................................................................................... 27

2.2

Plasmids, transfections, and antibodies ............................................................... 27

2.3

Quantification of infectious virus ........................................................................28

2.4

Western blotting...................................................................................................29

2.5

Reverse transcription polymerase chain reaction ................................................29

2.6

SNaPshot PCR .....................................................................................................30

2.7

Confocal Immunofluorescence Microscopy ........................................................ 30

2.8

Molecular Modelling ........................................................................................... 31

vi

CHAPTER 3: RESULTS ...................................................................................................33
3.1

Summary of the general biological characteristics of the current published
TRIM22 isoforms ................................................................................................ 33

3.2

The TRIM22α and TRMI22β isoforms exhibit different patterns of
localization ...........................................................................................................38

3.3

The B30.2/SPRY domain of TRIM22β is important for nuclear localization .....43

3.4

The TRIM22α and TRIM22β isoforms possess different degrees of HIV-1
restriction in the same cell type ...........................................................................48

3.5

The TRIM22α and TRIM22β isoforms restrict transcription from viral
promoters to varying degrees...............................................................................50

3.6

Several commonly used cell lines are negative for an SNP insertion in the
trim22 gene ..........................................................................................................53

CHAPTER 4: DISCUSSION ............................................................................................. 58
4.1

Limitations of this study ...................................................................................... 65

4.2

Future directions ..................................................................................................66

4.3

Conclusions..........................................................................................................67

REFERENCES ..................................................................................................................69
APPENDICES ...................................................................................................................86
CURRICULUM VITAE ....................................................................................................89

vii

LIST OF FIGURES
Figure 1: Schematic of the HIV-1 genome. ........................................................................ 2
Figure 2: Schematic outline of the HIV-1 lifecycle. ........................................................... 5
Figure 3: Schematic of interferon signaling pathways and induction of ISGs. .................. 9
Figure 4: Schematic representation of TRIM22 isoforms used in literature. ................... 16
Figure 5: Subcellular localization of endogenous TRIM22 in multiple cell lines. ........... 41
Figure 6: Subcellular localization of different TRIM22 isoforms in U2OS cells............. 44
Figure 7: Molecular modelling of the B30.2 domain from different TRIM22 isoforms. . 46
Figure 8: The TRIM22α and TRIM22β isoforms vary in their ability to restrict release of
infectious HIV-1 particles. ................................................................................................ 49
Figure 9: The TRIM22α and TRIM22β isoforms vary in their ability to restrict
transcription from viral promoters. ................................................................................... 51
Figure 10: The TRIM22α and TRIM22β isoforms block release of HIV-1 Gag-only
particles. ............................................................................................................................ 54

viii

LIST OF TABLES
Table 1: Summary of known single nucleotide polymorphisms (SNPs) in the trim22 gene.
........................................................................................................................................... 34
Table 2: Summary of trim22 clones used in literature. ..................................................... 36
Table 3: Summary of the localization patterns observed for TRIM22 in literature. ......... 39
Table 4: List of alleles present at nucleotide 1320 in commonly used cell lines, as
reported by SNaPshot PCR. .............................................................................................. 57

ix

LIST OF APPENDICES
Appendix 1: Sequence information for the TRIM22α isoform. ....................................... 86
Appendix 2: Sequence information for the TRIM22β isoform. ....................................... 87
Appendix 3: Ethics approval notice for use of human subjects. ....................................... 88

x

LIST OF ABBREVIATIONS
A3
AIDS
APOBEC
cDNA
CMV
ddNTP
DNA
EDTA
GFP
HBV
HCl
HIC
HIV-1
IFN
IRF-9
ISG
ISGF3
ISRE
Jak/STAT
LTNP
LTR
MDM
mRNA
NaCl
NFκB
NLS
OAS1
PAGE
PBMC
PKR
qRT-PCR
RBCC
RING
RIPA
RNA
SDS
SNP
Tat
TRIM
VLP
VMD

APOBEC3
Acquired immune deficiency syndrome
Apolipoprotein B mRNA-editing catalytic polypeptide-like
Complimentary DNA
Cytomegalovirus
Dideoxy nucleoside triphosphates
Deoxyribonucleic acid
Ethylenediaminetetraacetic acid
Green fluorescent protein
Hepatitis B virus
Hydrochloric acid
HIV controllers
Human immunodeficiency virus type 1
Interferon
Interferon regulatory factor 9
Interferon stimulated gene
Interferon stimulated gene factor 3
Interferon stimulated response element
Janus Kinases/Signal Transducers and Activators of Transcription
Long-term nonprogressors
Long terminal repeat
Monocyte derived macrophages
Messenger RNA
Sodium Chloride
Nuclear factor κ B
Nuclear localization signal
2´,5´-oligoadenylatesynthetase 1
Polyacrylamide gel electrophoresis
Peripheral blood mononuclear cell
Protein Kinase R
Quantitative reverse transcription polymerase chain reaction
Ring, B-Box, Coiled-coil
Really interesting new gene
Radioimmunoprecipitation Assay
Ribonucleic acid
Sodium dodecyl sulphate
Single nucleotide polymorphism
Trans-Activator of Transcription protein
Tripartite motif protein
Virus-like particle
Visual Molecular Dynamics

xi

1

CHAPTER 1: INTRODUCTION
1.1

Human Immunodeficiency Virus Type 1
Human immunodeficiency virus type 1 (HIV-1) is a retrovirus that primarily

infects CD4+ T lymphocytes (T cells), leading to gradual destruction of the immune
system and the eventual progression to Acquired Immune Deficiency Syndrome (AIDS).
The HIV-1 genome is approximately 9.7 kilobase pairs in length, and is composed of 9
genes that are flanked by two long terminal repeats (LTR) (Figure 1). The HIV-1 LTRs
have central roles in integration of the viral genome into the host cell genome, and
subsequent transcription of the integrated viral genes. The gag, pol, and env genes are
conserved among all retroviruses, and code for structural proteins, enzymes, and
envelope glycoproteins, respectively. Two regulatory proteins, Tat and Rev, also have
significant roles in HIV replication. Tat is important for efficient transcription from the 5‟
LTR and Rev is required for the transport of viral RNAs from the nucleus to the
cytoplasm. Finally, HIV-1 encodes 4 accessory proteins: Vif, Vpu, Vpr, and Nef. These
proteins are not essential for in vitro replication; however they possess a range of
important and interesting functions for productive infections, such as immune evasion
and counter-measures (reviewed in [1, 2]).
1.1.1

HIV-1 lifecycle
The HIV-1 lifecycle can be divided into early and late stages (Figure 2). In the

early stages, infection begins with adsorption of mature virions to CD4 receptors on the
target cell, which is mediated through the HIV surface glycoprotein gp120. Entry also
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Figure 1: Schematic of the HIV-1 genome.
The HIV-1 genome is approximately 9.7 kilobase pairs (kb) in length, and encodes 9
genes. Three genes (gag, pol, env) are common among all retroviruses, and are
synthesized as polyprotein precursors. HIV-1 also encodes 6 accessory proteins (tat, rev,
vif, vpr, vpu, nef), which are the primary translation products of spliced mRNA. Two of
these genes (tat and rev) contain spliced exons, as indicated by the dotted black lines.
Two long terminal repeats (LTR) boarder the genome, and have roles in integration,
replication, and transcription.
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requires binding to a chemokine co-receptor, which also determines viral tropism, and
which cell types it can infect. The two most common co-receptors are CCR5 and
CXCR4. CCR5 is expressed by macrophages and primary lymphocytes, and is important
during early stages of infection, such as HIV-1 transmission (reviewed in [1-3]). This
observation is highlighted by the resistance to HIV-1 infection in individuals
homozygous for the CCR5/Δ32 mutation, which encodes a non-functional CCR5 coreceptor [4-6]. Although CXCR4 is also expressed by primary lymphocytes, in many
patients the emergence of CXCR4- and dual-tropic (CXCR4 and CCR5) viral variants are
not observed until late stages of infection, typically around the onset of AIDS [7].
Binding of gp120 induces conformational changes in the HIV transmembrane protein
gp41, which in turn mediates fusion of the viral and host cell membranes [8]. Upon
capsid uncoating, several viral proteins remain associated with the negative-sense ssRNA
genome, including matrix and nucleocapsid structural components, the reverse
transcriptase and integrase enzymes, and Vpu. These proteins form the reverse
transcription complex and mediate reverse transcription of the genome into dsDNA.
From here the newly synthesized DNA associates with several viral and host proteins,
forming the preintegration complex, which is subsequently imported into the nucleus.
Once in the nucleus the viral integrase protein mediates integration of the viral dsDNA
into the host cell genome, completing the early stages of HIV-1 infection (reviewed in [1,
2]).
Late stages of the viral lifecycle begin with transcription of viral genes.
Transcription of the integrated provirus is directed from the viral 5‟ LTR, which contains
several promoter and regulatory elements, and requires both host and viral proteins
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Figure 2: Schematic outline of the HIV-1 lifecycle.
Infection begins with adsorption of mature viral particles to the host cell (primarily CD4+
T cells), mediated through binding of the viral envelope protein to a cellular CD4
receptor and chemokine co-receptor (most often CXCR4 or CCR5). Viral and cell
membranes fuse, releasing the virus capsid into the cytoplasm. The capsid is broken
down (uncoating), releasing the viral genome, two single strands of negative sense RNA,
and associated proteins (i.e. reverse transcriptase and integrase). The RNA is reversed
transcribed into double stranded cDNA, which is transported into the nucleus as part of
the pre-integration complex, and integrated into the host genomic DNA. Stages up to and
including integration encompass the early stages of the HIV-1 lifecycle. Late stages of
the HIV-1 lifecycle begin with transcription of the integrated viral DNA, which is
directed from the HIV-1 5‟ long terminal repeat (LTR) and enhanced by the viral Tat
protein. Viral messenger RNAs (mRNA), some of which are spliced, are exported into
the cytoplasm in a manner dependent on the viral Rev protein, and translated into viral
proteins. Envelope proteins are transported from the Golgi complex to the cell surface,
where they embed in the plasma membrane. Gag polyproteins, some associated with
genomic RNA, are targeted to the membrane where they oligomerize and direct budding
of nascent particles through the membrane. After release, the Gag polyprotein is
subsequently cleaved into its domains (matrix, capsid, nucleocapsid and p6) by the
virion-encoded protease. This allows structural and morphologic rearrangement, such as
condensation of the core into a cone-shaped structure, and generates mature, infectious
particles.
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(reviewed in [9]). The core promoter contains a TATA element, and three tandem Sp1
binding sites which are critical to viral transcription [10, 11]. Upstream of the core
promoter is the enhancer, which contains binding sites for three transcription factors
(NFκB, NFAT, AP-1) that are involved in viral transcription in T lymphocytes following
activation [12-14]. The NFκB binding motif is conserved in all HIV-1 isolates, and is
vital to viral transcription [15-17]. Likewise, the HIV-1 Trans-Activator of Transcription
protein (Tat) is indispensible for HIV-1 infection, and enhances LTR-directed
transcription by hundreds to thousands fold [18, 19]. Tat functions by binding the TAR
element, a secondary RNA structure formed by the 5‟ end of all nascent HIV-1
transcripts. Once bound, Tat is involved in recruiting cellular cofactors and stabilizing
RNA polymerase II [20]. Notably, without a functional Tat protein, transcripts are
randomly and prematurely terminated, and progeny virions are not produced [18, 19].
Nascent viral transcripts are exported from the nucleus via the viral Rev protein,
and are translated in the cytoplasm using normal host machinery. Envelope glycoproteins
are targeted to, and assemble on the outside of the host cell membrane, awaiting viral
assembly – a process that is driven via the Gag polyprotein (Pr55Gag). Interestingly,
expression of Gag alone is sufficient for the formation of noninfectious virus-like
particles (VLPs) [21]. Pr55Gag contains four major domains, each of which have
important roles in HIV assembly and release. In brief, the N-terminal matrix domain
targets Pr55Gag to the site of assembly at the plasma membrane, the capsid domain
facilitates multimerization of Pr55Gag polyproteins, the nucleocapsid domain binds the
ssRNA genome, and the p6 domain recruits cellular proteins important for budding and
release (reviewed in [22-24]). Upon release the viral protease cleaves the Pr55Gag
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polyprotein into its respective domains, forming the structural components of the HIV
virion [25]. This process is called maturation, and is the final step in creating infectious
HIV particles [26].
1.2

The interferon response
The interferon (IFN) system is a key mediator of the innate immune response, and

the first line of defense against viral infections. IFNs are a class of cytokines produced
and secreted in response to external stimuli, such as viral infection, and signal
neighbouring cells to initiate an antiviral state. The three major types of IFNs (type I-III)
are differentiated based on the receptors they bind (Figure 3), with each type also having
slightly different sets of functions. Type I IFNs (α, β, ε, κ, ω) are indispensible for
defence against many viruses, and the two main subtypes, IFN-α and IFN-β, are produced
by almost every cell in the body. All type I IFNs signal through a common, ubiquitously
expressed interferon alpha receptor (IFNAR) – a heterodimeric receptor composed of the
IFNAR1 and IFNAR2 subunits. Similarly, type II IFN (IFN-ɣ) bind to an interferon
gamma receptor (IFNGR) composed of the IFNGR1 and IFNGR2 subunits. In contrast to
type I IFNs, type II IFNs have a larger role in immune regulation as opposed to direct
antiviral actions, and is primarily released by immune cells, such as NK or effector T
cells (reviewed in [27-31]. Type III IFNs (IFN-λ) signal through a third heterodimeric
receptor, which is composed of an IFNλR1 chain and an IL-10R2 chain, and is primarily
expressed on epithelial cells. Although type III IFN is a relatively new and distinct
member of the IFN family, it appears to share many similarities to type I IFNs, including
expression patterns, induction mechanisms, and biological activities (reviewed in [2831]).
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Figure 3: Schematic of interferon signaling pathways and induction of ISGs.
The three major types of IFNs (type I-III) are separated based on the receptors they bind.
Type I IFNs (α, β) signal through the interferon alpha receptor (IFNAR), composed of the
IFNAR1 and IFNAR2 subunits. Type III IFNs (IFN-λ) bind a heterodimeric receptor
composed of an IFNλR1 chain and an IL-10R2 chain. Both type I and III IFN receptors
associate with the Tyk2 and Jak1 kinases, resulting in the tyrosine phosphorylation and
activation of STAT2 and STAT1. STAT1 and STAT2 combine with IFN regulatory
factor 9 (IRF-9) to form the transcription factor complex IFN stimulated gene factor 3
(ISGF3), which translocates to the nucleus and interacts with IFN-stimulated response
elements (ISRE) to regulate transcription of interferon stimulated genes (ISGs). In
contrast, type II IFN (IFN-ɣ) binds as a dimer to the interferon gamma receptor (IFNGR)
composed of two IFNGR1 and IFNGR2 subunits. The IFNGR1 and IFNGR2 receptors
associate with Jak1 and Jak2 and result in the phosphorylation and activation of STAT1
alone. STAT1 homodimers translocate to the nucleus and are capable of binding
alternative promoter elements, such as gamma activated sites (GAS), and regulating
transcription of other IFN-responsive genes.
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Binding of IFNs to their associated receptors activates a Janus Kinases/Signal
Transducers and Activators of Transcription (Jak/STAT) signalling cascade that
ultimately results in the upregulation of a vast array of interferon stimulated genes (ISGs)
(Figure 3). Both type I and III IFN receptors associate with the Tyk2 and Jak1 kinases
through the IFNAR1/IL-10R2 and IFNAR2/IFNλR1 receptor subunits, respectively. This
association results in the tyrosine phosphorylation and activation of STAT2 and STAT1,
which together with IFN regulatory factor 9 (IRF-9), form the transcription factor
complex IFN stimulated gene factor 3 (ISGF3). Upon formation, ISGF3 translocates to
the nucleus and regulates transcription though binding to IFN-stimulated response
elements present in the promoters of certain ISGs. Alternatively, the IFNGR1 and
IFNGR2 receptors associate with Jak1 and Jak2, respectively, leading to the
phosphorylation and activation of STAT1 alone. In addition, all IFN signalling pathways
can lead to the formation of STAT1–STAT1 homodimers capable of binding alternative
promoter elements (Gamma activated sites) and regulating transcription of other IFNresponsive genes (reviewed in [27-31].
Many interferon-induced proteins, termed cellular restriction factors, have been
identified to have specific antiviral functions that target various stages of the viral
lifecycle. For instance, the ubiquitin-like molecule ISG15 is noted to be one of the most
upregulated genes in response to IFN. Interestingly, several proteins with important roles
in the type I IFN response have been identified as putative targets for modification with
ISG15 (termed ISGylation) [32]. ISG15 has also been reported to help prevent viral
counteraction of the IFNβ response [33], to possess immune modulatory capabilities [34],
and several studies in mice have shown that ISG15 deficiency corresponds to increased
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susceptibility to multiple viruses (reviewed in [31]). Furthermore, ISG15 has been shown
to restrict the replication of a range of viruses [35-42], including Influenza A [35-38],
Ebola [40], and HIV-1 [41, 42].
Similarly, other well-known IFN-induced antiviral proteins, such as Protein
Kinase R (PKR) and 2´,5´-oligoadenylatesynthetase 1 (OAS1)/RNaseL, are expressed at
basal levels in addition to being highly upregulated in response to IFN, allowing them to
serve as both viral sensors and antiviral effectors. These proteins sense viral infection and
are activated by the presence of dsRNA, which is not normally present in uninfected
cells. This activation signals inactive OAS1 monomers to oligomerize and synthesize
2‟,5‟-oligoadenylates, which in turn activate RNaseL, a ribonuclease that degrades viral
and cellular RNA. Similarly, activation of PKR results in the dimerization of inactive
monomers, forming a functional protein capable of inhibiting translation (reviewed in
[31, 43, 44]). Interestingly, both of these proteins have been shown to be activated by,
and to possess antiviral activity against HIV-1 infection [45-48].
Not surprisingly, the actions of type I IFNs on HIV-1 replication have been
extensively studied. Type I IFN treatment of cells in vitro interrupts both early [49-51]
and late stages of the viral lifecycle [52-55]. The use of type I IFN to treat HIV-1 patients
has also had success [56-60], but has come under scrutiny due to adverse effects [61].
Similarly, antiretroviral drugs have failed to provide a cure due to the emergence of drugresistant strains [62] and toxicity-induced patient noncompliance [63]. In addition, an
effective HIV-1 vaccine has yet to come to fruition (reviewed in [64]). In an attempt to
develop new strategies against HIV infection, much research has been conducted on the
mechanisms of action for different cellular HIV-1 restriction factors (reviewed in [43]).
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1.3

HIV-1 restriction factors

1.3.1

APOBEC3
One of the best characterized HIV-1 restriction factor families is the human

apolipoprotein B mRNA-editing catalytic polypeptide-like 3 (APOBEC3) family. There
are seven members of APOBEC3 proteins (A-H), all of which are cytidine deaminases
capable of converting cytosine to uracil in RNA or DNA, and all have some degree of
activity to mutate and restrict HIV-1 (reviewed in [65]). APOBEC3G (A3G) was the first
member identified to block HIV-1 infection, and also appears to be the most potent
family member against HIV-1 [66]. In the absence of HIV-1 Vif, A3G is packaged into
newly formed virions and subsequently imparts its antiviral action upon infection of a
new cell. During reverse transcription, A3G induces cytidine deamination (C→U
mutations) in the negative strand of newly synthesized viral cDNA. This results in G→A
hyper-mutation of the viral genome, and consequently the possibility for the production
of premature stop codons or mutated, non-functional viral proteins [67-74]. In addition,
A3G is known to function in a deaminase-independent manner by interfering with reverse
transcription [75-78], and has been linked to decreased accumulation of viral cDNA [74,
79-84]. Nevertheless, HIV-1 possesses an A3G counter-measure in the Vif protein, which
is capable of restoring infectivity by inducing the degradation of multiple APOBEC3
proteins [70, 85-89].
1.3.2

Tetherin
In contrast to APOBECs, the restriction factor tetherin (Bone Marrow Stromal

Cell Antigen 2; CD317) blocks late stages of HIV-1 replication [90]. Tetherin is a
transmembrane protein capable of binding the host cell and viral membranes during the
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viral assembly/release stage. Binding results in the accumulation of HIV-1 particles at the
cell membrane in a chain-like fashion [91], and ultimately induces the reinternalization of
released particles and their subsequent degradation within the cell [92]. Although the
exact mechanisms behind tetherin-mediated restriction are still unclear, certain aspects
have been elucidated, including the fact that dimerization of tetherin is required for HIV1 restriction [93]. Nevertheless, HIV-1 also encodes a tetherin counter-measure in the vpu
gene, limiting tetherin‟s effectiveness to HIVΔVpu strains [90]. Similar to Vif-induced
degradation of A3G, the Vpu protein is capable of targeting tetherin for degradation,
restoring effective release of mature HIV-1 virions from the host cell [90, 94]. The details
of Vpu-mediated degradation are still uncharacterized, however two major hypotheses
currently exist. One theory involves the post-translational ubiquitination of tetherin [9597], leading to subsequent endocytosis from the cell membrane and degradation [92, 94,
98]. The second theory states that tetherin trafficking to the plasma membrane is blocked,
and is instead delivered to late endosomal compartments [99, 100].
1.4

Tripartite Motif (TRIM) Proteins
Some restriction factors, such as members of the Tripartite Motif (TRIM) family

(TRIM5α and TRIM22), can target multiple stages of the HIV-1 lifecycle. The TRIM
family is a class of innate immune proteins with widespread antiviral activity. There are
currently 75 identified members, all containing a highly conserved “RBCC” motif (RING
domain, one or two B-box domains, and a predicted Coiled-Coil region) (reviewed in
[101]) (Figure 4). The N-terminal RING (Really interesting new gene) domain contains a
specialized zinc finger that coordinates two zinc atoms, and many RING proteins have
been shown to have E3 ubiquitin ligase activity [102, 103]. Considerably less is known
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about the other domains of TRIM proteins. The B-box domain is unique to TRIM
proteins and also contains a zinc finger. Although the function of these domains is not yet
known, the B-box 2 of TRIM5α is important in forming higher-order associations among
TRIM5α oligomers, and mutations result in reduced binding to the HIV-1 capsid protein
[104]. The B-box domain is followed by a predicted coiled-coil region, which is believed
to be involved in oligomerization of at least some TRIM proteins, such as TRIM22 [105].
The RBCC motif is often followed by a C-terminal domain, which for 60% of TRIM
proteins, including TRIM22, is a B30.2/SPRY domain [101]. Although the exact function
of the SPRY domain is still unclear, it is believed to be involved in RNA binding [106]
and/or protein-protein interaction [107]. This domain also appears to have essential links
to antiviral activity, as observed in studies of HIV-1 restriction by TRIM5α [108].
1.4.1

TRIM5α
TRIM5α is the earliest acting HIV-1 restriction factor currently known. Before

TRIM5α was identified as an HIV-1 restriction factor, it was observed that HIV-1 could
enter the cells of Old World monkeys, such as the rhesus macaque; however the virus
was blocked from producing a productive infection [109-111]. This introduced the idea
of species-specific restriction of HIV-1 replication, and from here it was discovered that
the rhesus macaque TRIM5α (RhTRIM5α) was capable of potently restricting HIV-1
replication [112]. Further research has indicated that restriction is believed to be due to
specific recognition of the HIV-1 capsid protein through the C-terminal B30.2 domain of
RhTRIM5α, resulting in premature disassembly of the capsid during infection [113]. In
addition, RhTRIM5α appears to interfere with HIV-1 reverse transcription and nuclear
import of the viral cDNA [114-116]. Although controversial, RhTRIM5α also blocks late
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Figure 4: Schematic representation of TRIM22 isoforms used in literature.
All tripartite motif (TRIM) proteins contain a highly conserved “RBCC” (Ring, one or
two B-Boxs, Coiled-Coil) motif, followed by a C-terminal domain, the most common of
which is the B30.2/SPRY domain. The start/end amino acid positions of each domain are
indicated below each isoform. The locations of SNPs are reported in relation to the
TRIM22β/BC035582 sequence, and are depicted by yellow bands. The bi-partite and
„KRK‟ nuclear localization signals (NLS) located at amino acids 257/265 and 380 are
depicted by purple and blue bands, respectively. A) TRIM22β is commercially available,
and matches the consensus sequence for trim22. B) HQ_842635 was cloned from U937
cells, and contains SNPs at nucleotides 463 and 725, resulting in two amino substitutions:
D155N, and R242T. C) The first trim22 clone, X82200, was created from a splice variant
missing nucleotides 519-531, resulting in a 4 amino acid deletion from the coiled-coil
domain. It contains an SNP at nucleotide 725, resulting in the R242T substitution. A
single nucleotide deletion at nucleotide 1316 causes a frameshift mutation and the
production of a premature stop codon at nucleotide 1326. The resulting protein is 442
amino acids, and contains the unique C-terminal sequence „LPVVLGFS‟. D) TRIM22α
was cloned using primers based on X82200. It also lack nucleotides 519-531, and
contains the R242T substitution, however there is no deletion at nucleotide 1316. As a
result, there is no premature stop codon at nucleotide 1326, and the clone runs 18
nucleotides into the pcDNA3.1 backbone, creating the unique C-terminal sequence
„ARACI‟.
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stages of HIV-1 infection by targeting the Gag polyprotein for degradation and
interfering with viral assembly [117-119]. Interestingly, the human TRIM5α homologue
(HuTRIM5α) possesses little to no antiviral activity against HIV-1 replication [112].
Furthermore, the lack of restriction by HuTRIM5α has been mapped to a single amino
acid mutation (R332P) in the B30.2 domain [108], and restoration of a proline at this
position restores capsid binding capabilities and greatly improves HIV-1 restriction by
HuTRIM5α [120].
1.4.2

TRIM22
Human TRIM22 (also known as Stimulated trans-acting factor 50, Staf-50) was

originally isolated in 1995 during a search for IFN-induced genes in Daudi cells, a well
characterized B lymphoblast cell line [121]. The trim22 gene is located at chromosomal
position 11p15, immediately adjacent to the TRIM5α gene [122]. TRIM22, along with
TRIM5α, have been under positive selection episodically for approximately 23 million
years; however these two genes have evolved in a mutually exclusive manner, with only
one being selected for in a given primate lineage [123]. Although relatively little is
known about the function of TRIM22 within the cell, it may play a role in cellular
processes such as cell differentiation/proliferation [124, 125], and in diseases such as
Wilms tumor [126, 127] and systemic lupus erythematosus [128]. TRIM22 is
constitutively expressed in resting T cells [129], is a known p53 target gene [124] and
NFκB activator [130], and is upregulated in response to type I and II IFNs [121, 122, 125,
131-136]. In addition, its expression is altered in response to a variety of stimuli,
including T-cell activation/co-stimulation [129, 135], multiple cytokines [135, 137], and
multiple viral antigens/infections [138-143]. Furthermore, TRIM22 has been shown to
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have antiviral activity against HIV-1 [131, 134, 144, 145], Hepatitis B virus (HBV)
[132], and encephalomyocarditis virus [146].
1.5

TRIM22 inhibits HIV-1 Replication
Despite being identified as a potential HIV-1 restriction factor over a decade ago,

relatively little is known about the effect of TRIM22 on HIV-1 replication. TRIM22 was
first discovered by Tissot and Mechti in 1995 during a search for IFN-induced genes in
Daudi cells [121]. It was also noted that TRIM22 displayed high homology to the mouse
Rpt-1 gene, which had previously been shown to down-regulate expression from the
HIV-1 LTR [147]. Similarly, exogenous expression of TRIM22 was observed to downregulate transcription from the HIV-1 LTR in the COS7 cell lines [121]. Although this
was performed using a luciferase reporter gene under the control of the LTR as opposed
to an HIV-1 proviral genome, it provided the first evidence suggesting that TRIM22 may
block HIV-1 transcription and ultimately replication.
In 2006, TRIM22 was shown to be highly upregulated in primary monocytederived macrophage (MDM) in response to HIV-1 infection or IFNα treatment.
Exogenous expression of TRIM22 was subsequently shown to inhibit HIV-1 infection up
to 50% in 293T cells modified to express the CD4 and CCR5 receptors. Furthermore, cotransfection of TRIM22 with plasmids encoding a lentiviral packaging system based on
the HIV-1 structure (M107, pMD-G and pCMV-ΔR8.9) resulted in reduced titres of
pseudotyped virus compared to an empty vector control. Interestingly, in this
pseudotyped virus system, expression of HIV-1 genes is directed from a cytomegalovirus
(CMV) promoter (pCMV-ΔR8.9) as opposed to an actual HIV-1 LTR [131]. Since
TRIM22 has been shown not to restrict transcription from the CMV promoter in 293T

20
cells [144], it serves to show that the potent restriction observed in 293T cells must be a
result of TRIM22 acting at a separate late stage of the HIV-1 lifecycle. In addition, the
over-expression of TRIM22 in primary MDM was also shown to restrict HIV-1 infection
by 70-90%, and was capable of preventing the formation of syncytia [131]. Together,
these experiments provided the first evidence that TRIM22 can restrict HIV-1 replication
in vitro, and suggested that TRIM22 may possess transcription-independent antiviral
activity.
In 2008, Barr, et al. provided the first mechanistic data linking TRIM22 to
restriction of HIV-1 replication. TRIM22 was shown to be highly upregulated in response
to IFNβ treatment of HOS cells modified to express the CD4 and CXCR4 receptors
(HOS-CD4/CXCR4). These cells support robust HIV-1 replication, which can be
attenuated by IFNβ. Moreover, TRIM22 was shown to be an integral part of the IFNβ
response against HIV-1 infection, noting that IFNβ-induced restriction of HIV-1
replication was abolished after shRNA knockdown of TRIM22. In addition, exogenous
over-expression of TRIM22 was shown to inhibit HIV-1 replication in several other cell
lines. Interestingly, in the HOS and HeLa cell lines, TRIM22 expression repressed
release of HIV-1 particles into the supernatant, but had no effect on the intracellular
levels of HIV-1 Gag. Conversely, in the U2OS and 143b cell lines, both the release of
HIV-1 particles into the supernatant as well as intracellular levels of Gag were decreased
in the presence of TRIM22 [134].
Restriction in HOS-CD4/CXCR4 cells also appeared to be independent of any
effect on the HIV-1 LTR, as TRIM22 was also shown to restrict the release of virus-like
particles containing only the Gag protein expressed from the CMV promoter.
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Furthermore, this restriction was determined to be a result of altered Gag trafficking to
the plasma membrane. Although no mechanism of action was ever studied in U2OS or
143b cells, several possibilities could explain the observed decrease of intracellular Gag,
including inhibition of transcription or degradation of the Gag polyprotein. It is notable
that the antiviral actions of TRIM22 were E3 ligase-dependent, and TRIM22 was shown
to interact with HIV-1 Gag specifically [134]. This could suggest that TRIM22 mediates
the ubiquitination of Gag, resulting in altered trafficking or proteasomal degradation,
depending on the position and number of ubiquitin molecules [148]. Nevertheless,
TRIM22 appears to have several distinct activities depending on the cell-line being used
for investigation.
It appears that TRIM22 is capable of restricting HIV-1 replication through at least
two mechanisms: by targeting trafficking of the Gag polyprotein to the plasma
membrane, as well as by down-regulating transcription from the HIV-1 LTR.
Interestingly, clones of the U937 promonocytic cell line have been previously described
as either permissive or nonpermissive, based on their efficient or inefficient support of
HIV-1 replication [149]. Investigation of these clones revealed that trim22 expression
could only be detected in nonpermissive clones, whereas other IFN-induced restriction
factors were readily detected in both subsets. In addition, use of a luciferase reporter
plasmid under the control of the HIV-1 LTR revealed that LTR-mediated transcription
was decreased 7-10 fold in nonpermissive clones, which was recoverable to levels
observed in permissive cells via shRNA knockdown of trim22 expression. Furthermore,
exogenous expression of TRIM22 in permissive clones resulted in decreased LTR
transcription comparable to that observed in nonpermissive clones. Similar results were
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observed in the A3.01 T cell line, further supporting the effects of TRIM22 on HIV-1
infection in critical cell targets [144].
The first clinically relevant evidence to support a role for TRIM22 as an anti-HIV
effector in vivo was provided in 2011. A study monitoring gene expression in high-risk
HIV-1 negative individuals detected a positive correlation between TRIM22 expression
and increased control of HIV-1 infection. It was observed that IFNβ and TRIM22 levels
in peripheral blood mononuclear cells (PBMCs) were increased in patients after HIV-1
infection. In addition, infected patients expressing higher TRIM22 levels exhibited
significantly lower viral loads and significantly higher CD4+ T cell counts, suggesting
that TRIM22 may play a role in controlling HIV-1 infection. Furthermore, knockdown of
TRIM22 in the Jurkat T cell line resulted in increased HIV-1 particle release and
replication in vitro. Surprisingly, a significant inverse correlation was observed between
the closely related IFN-inducible TRIM5α protein and IFNβ expression [145].
Nevertheless, these results suggest that human TRIM22 may be an important protein in
controlling HIV-1 and/or other retrovirus infections, and additional studies will be
required to determine the prevalence of TRIM22 forms and their relation to antiviral
capability in vivo.
1.6

Rationale for studying innate viral restriction factors
As of 2010, the World Health Organization estimates that approximately 34

million people worldwide are infected with HIV. Although the majority of infected
individuals eventually progress to AIDS, especially in the absence of highly active antiretroviral therapy (HAART), a small percentage appear to possess levels of natural
resistance to infection. Two general phenotypes are observed among these resistant
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individuals:

Long-term

nonprogressors

(LTNP)

and

HIV

controllers

(HIC).

Approximately 5% of infected individuals are classified as LTNP, and are defined by the
ability to maintain high CD4+ T-cell counts in the absence of HAART for 10 years or
more. Levels of viral RNA in the blood and viral DNA in PBMCs is quite variable
between individuals, and the majority of LTNP eventually experience a decline in their
CD4+ T cell counts. In comparison, less than 1% of infected individuals are classified as
HIC, as defined by having extremely low viral DNA in PBMCs, undetectable levels of
viral RNA in the blood, and rarely showing signs of disease progression. Conversely,
approximately 5% of individuals also experience accelerated infection kinetics,
progressing to AIDS within 1-3 years of infection (Reviewed in [150-152]).
Interestingly, the phenomenon of viral control during HIV infection appears to be
spontaneous and multifactorial, with variable causes. Although the exact determinants
responsible for rate of progression are largely unknown, several elements have been
identified as contributing factors to prolonged control during HIV-1 infection, including
strong CD4+ and CD8+ T cell responses [153]. Nevertheless, adaptive immune responses
require time to develop, thus it is also believed that a number of innate immune
mechanisms are important in limiting replication during early infection, allowing for the
later development of strong T-cell responses [154, 155].
The role of innate cellular restriction factors in viral control is both controversial
and insufficiently studied. Thus far, the primary focus has been on potential effects of
APOBEC3 (A3) proteins, for which there are reports both supporting [156-158] and
refuting [159, 160] potential involvement in control of HIV-1 infection. However, A3
activity may also be misrepresented due to some reports not accounting for potential A3
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deaminase-independent mechanisms [79], and the fact that some A3 proteins can be
counteracted by the HIV-1 Vif protein [161]. Interestingly, loss of functional A3B was
found to be associated with an increased risk of HIV-1 acquisition, higher viral setpoints,
and accelerated disease progression [162]. Other reports have argued against the
involvement of cellular restriction factors based on the observation that CD4+ T cells
from HIC are susceptible to HIV-1 infection in vitro [163]. Alternatively, other reports
have noted that HIC CD4+ T cells exhibit decreased susceptibility to HIV-1 infection,
which was associated with decreased viral reverse transcription, integration, and mRNA
transcription [164, 165]. Furthermore, the involvement of cellular factors was suggested,
as knockdown of p21, a factor previously implicated in control of HIV-1 replication [166,
167], resulted in increased viral reverse transcripts and mRNA production in CD4+ T
cells from HIC. It was also noted that resistance to infection could be overcome with high
viral inocula [164, 165]. Regardless, this narrow focus and lack of research has resulted
in the under-appreciation of HIV-1 restriction factors as potential contributors to control
of HIV-1 infection.
A number of genetic factors are also believed to have a role in some cases of HIV
control. It has been observed that individuals homozygous for the aforementioned
CCR5/Δ32 mutation are resistant to HIV-1 infection [4-6], and a heterozygous genotype
is associated with a number of LTNP [6, 168, 169]. Alternatively, it has been observed
that mutations in the CCR5 promoter resulting in increased CCR5 expression are
associated with rapid progression to AIDS [170]. In addition, certain human leukocyte
antigen (HLA) haplotypes appear to be associated with disease progression, such as
HLA-B57 and HLA-B27, which are consistently overrepresented in HICs [163, 171-
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174]. Interestingly, single-nucleotide polymorphisms (SNPs) have been identified as a
contributing factor to variation in viral load set-points during asymptomatic early
infection [175] – a stage that holds important implications for rate of disease progression
[176].
A SNP is defined as a single nucleotide variation in a given genomic DNA
sequence between an individual and other members of that species. Biological
consequences of SNPs can vary from benign synonymous mutations, and missense
mutations resulting in single amino acid substitutions, to more severe nonsense and
frameshift mutations. These mutations result in the production of a premature stop
codons and vastly altered amino acid sequences, respectively, which in turn can
potentially lead to inactivation of the normal biological activity of the affected protein.
Interestingly, it has been observed that SNPs in the TRIM5α gene may have an impact on
both the susceptibility to HIV-1 infection, as well as the clinical course of HIV-1
infection [177, 178]. Similarly, certain SNPs in the APOBEC3H gene have been shown to
have effects on the stability and subcellular localization of A3H, which subsequently
corresponded to variable degrees of HIV-1 restriction. Furthermore, A3H variants were
also resistant to Vif, the HIV-1 protein responsible for the degradation of A3F/G [179181]. In addition, an association of certain A3H haplotypes with natural resistance to
HIV-1 infection was observed, highlighting the fact that SNPs and restriction may have
implications on disease progression to AIDS [182].
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1.7

Hypothesis and specific aims
Preliminary data obtained in the Barr laboratory has identified a long and short

isoform of TRIM22, resulting from one of many SNPs in the trim22 gene. These
naturally occurring differences in the trim22 gene can be exploited to further investigate
the biological role(s) of TRIM22, and to help elucidate specific domains and amino acids
that are important for its functions. The overall objective of my thesis project was to
characterize a long and short isoform of TRIM22 and compare their ability to inhibit
HIV-1 replication. I hypothesized that these long and short isoforms of TRIM22 differ in
their ability to restrict HIV-1 replication, and that this difference is attributed to different
mechanisms of restriction.
To address this hypothesis, my specific aims are:
(i)

To identify and associate currently published TRIM22 isoforms to known
TRIM22 functions.

(ii)

To determine the pattern of localization of the long and short TRIM22 isoforms.

(iii)

To compare the restrictive capabilities of the long and short TRIM22 isoforms.

(iv)

To compare the ability of the long and short TRIM22 isoforms to restrict viral
transcription.

(v)

To identify the allele present at a known trim22 SNP in commonly used cell lines.
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CHAPTER 2: MATERIALS AND METHODS
2.1

Cells and cell lines
Cells were maintained in standard growth medium (Dulbecco‟s Modified Eagle‟s

Medium for adherent cells and RPMI-1640 for suspension cells), supplemented with 10%
heat-inactivated Fetal Bovine Serum, 100 U/mL Penicillin and 100 μg/mL Streptomycin
at 37°C with 5% CO2. Cell lines were obtained from American Type Culture Collection
unless otherwise stated. HOS-CD4/CXCR4 was provided by Dr. F. Bushman (University
of Pennsylvania, USA). The following reagent was obtained through the NIH AIDS
Research and Reference Reagent Program, Division of AIDS, NIAID, NIH: (GHOST (3)
R3/X4/R5; Cat. 3943) from Dr. Vineet N. KewalRamani and Dr. Dan R. Littman [183].
PBMCs were isolated from whole blood from healthy volunteers using a Ficoll Hypaque
(Sigma) gradient according to the manufacturer‟s instructions. Informed consent was
obtained from all subjects according to the ethics protocol #16682E, approved by The
University of Western Ontario Research Ethics Board for Health Sciences Research
Involving Human Subjects (HSREB) (Appendix 3).
2.2

Plasmids, transfections, and antibodies
The plasmid encoding TRIM22α (pTRIM22α) was previously described by Barr,

et al. [134], and the TRIM22β plasmid (pTRIM22β) was purchased from Open
Biosystems. Both plasmids were previously modified by our lab to express N-terminal
HA-FLAG tags. The plasmid encoding TRIM22β containing a deleted B30.2 domain
(TRIM22β-ΔB30.2) was previously generated in our lab, and is also N-terminally FLAGtagged. The promoterless empty vector plasmid pGL3 was purchased from Promega. The
plasmid encoding codon-optimized Gag (pGag) was obtained through the NIH AIDS
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Research and Reference Reagent Program, Division of AIDS, NIAID, NIH from Drs.
Yingying Li, Feng Gao and Beatrice H. Hahn (p96ZM651gag-opt) [184]. The plasmid
encoding the replication-competent provirus HIV-1 R9 was obtained from Dr. F.
Bushman (University of Pennsylvania, USA). All plasmid transfections were performed
using Lipofectamine 2000 (Invitrogen), except for the Gag release western blot, which
was performed using FuGene HD. Co-transfections were performed at a 5:1 ratio (pGL3,
pTRIM22α, or TRIM22β: pR9 or pGag-opt respectively). Antibodies: anti-TRIM22 was
obtained from Abnova, anti-FLAG from Sigma, and anti-β-actin from Rockland. The
following reagents were obtained through the NIH AIDS Research and Reference
Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 p24 Monoclonal Antibody
(183-H12-5C) from Dr. Bruce Chesebro and Kathy Wehrly [185-187].
2.3

Quantification of infectious virus
Clarified supernatants containing virus particles were pelleted over a 20% sucrose

cushion for 2 hours at 21,000 × g. Pellets were resuspended in 300 µL fresh medium with
polybrene (20µg/mL), and used to infect GHOST(3) indicator cells at approximately 50%
confluency in a 12-well plate. Infection was allowed to proceed for 2-3 hours, after which
the virus media was removed and replaced with 1 mL of fresh media. Approximately 3648 hours later media was removed, and cells were harvested in 800 µL of 1x phosphate
buffered saline (PBS)/10 mM EDTA. Samples were added to 5 mL round bottom tubes
containing 200 µL of 10% formaldehyde in PBS (final concentration of 2%
formaldehyde), and allowed to fix for at least 10 minutes before samples were analyzed
for GFP expression by flow cytometry.
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2.4

Western blotting
Clarified supernatants containing Gag-only particles were pelleted over a 20%

sucrose cushion for 2 hours at 21,000 × g. Cells were detached, centrifuged at 350 × g for
5 minutes, and washed twice with PBS. Supernatant or cell pellets were lysed with 1×
RIPA buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1× Complete
Protease Inhibitor (Roche), 1% Triton X-100, 0.1% SDS). For quantitative Western
blotting, samples were mixed with 4× loading buffer (40% Glycerol, 240 mM Tris/HCl
pH 6.8, 8% SDS, 0.04% bromophenol blue, and 5% beta-mercaptoethanol) to a final 1×
concentration and separated on a 10% SDS-PAGE gel. Protein was transferred to
FluorTransW (Pall) membrane by semi-dry transfer. Western blotting was carried out by
blocking the membrane for 1 hour in Li-cor Blocking Buffer (Li-cor Biosciences)
followed by an overnight incubation with 1:1000 dilution of primary antibody at 4°C.
Detection was carried out using IR dye-labelled secondary antibody (1:20,000 for 30
minutes at room temperature) and the Li-cor Odyssey Detection System (Li-cor
Biosciences). Densitometric analysis was performed using ImageJ 1.43 u 64-bit version
software (NIH, USA).
2.5

Reverse transcription polymerase chain reaction
Total RNA was isolated from transfected cell lysates using the PureLink RNA

Mini Kit (Invitrogen) and reverse transcribed using M-MLV reverse transcriptase and
poly dT primers according to manufacturer‟s instructions (Invitrogen). Quantitative realtime PCR was performed using Brilliant II SYBR Green QPCR Master Mix (Agilent
Technologies) and primer pairs specific for HIV-1 Gag (fwd: 5‟ AAT GAT GAC AGC
ATG TCA GGG 3‟; rev: 5‟ TAC AGT TCC TTG TCT ATC GGC 3‟), or β-actin (fwd: 5‟
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GGT CAT CAC CAT TGG CAA TGA GCG G 3‟; rev: 5‟ GGA CTC GTC ATA CTC
CTG CTT GCT G 3‟). Results were expressed as the relative fold-difference between
control cells and cells expressing TRIM22.
2.6

SNaPshot PCR
Total genomic DNA was isolated from cell lysates using the PureLink Genomic

DNA Mini Kit (Invitrogen), and a 597 base pair region of the trim22 B30.2 domain was
amplified by PCR using the following primers: TRIM22 forward- 5‟ GGA TCA GAG
ACA AGT GAA AAC TTT TGG TGT CTT CGG CTG CC 3‟; TRIM22 reverse- 5‟
ACG TTC TAG ATC AGG AGC TCG GTG GGC ACA CAG 3‟. Samples were sent for
SNaPshot PCR analysis using the primer: TRIM22 SNP primer 5'- AGG AAA ACC
CCA ATA CGA CAG GG -3'. This unique primer binds directly upstream of the SNP of
interest,

and

a

PCR

extension

is

performed

using

fluorescence

labelled

dideoxynucleotides (ddNTP), with each of the four nucleotides (A, T, C, G) conjugated
to a different wavelength molecule. The use of ddNTPs ensures only one base is added
during the extension, providing a specific fluorescent signal corresponding to the
incorporated nucleotide, representing the allele present at the SNP of interest.
2.7

Confocal Immunofluorescence Microscopy
Adherent cells were cultured overnight in 12-well plates on 18 mm coverslips to

approximately 80% confluency. For suspension cells, approximately 1 x 106 cells/well
were seeded into 12-well plates immediately prior to interferon treatment. For interferon
stimulation, media was replaced with fresh media containing recombinant human
interferon β-1b (Pestka Biomedical Laboratories) at a final concentration of 500 U/mL.
For suspension cells, following a 24 hour treatment with IFN-β, cells were centrifuged at
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350 × g for 5 minutes, resuspended in 300 µL of 1x PBS, and allowed to settle on poly-Llysine coated coverslips for at least 1 hour at 37°C. For transfections, cells were
transfected with pTRIM22α, pTRIM22β, or pTRIM22β-ΔB30.2 using Lipofectamine
2000 according to manufacturer‟s instructions (Invitrogen). Twenty-four hours posttransfection/stimulation, the coverslips containing the cells were washed twice with PF
buffer (1× PBS + 1% FBS), and fixed for 10 minutes in 1× PBS containing 5%
formaldehyde and 2% sucrose, permeabilized in 1× PBS containing 5% NP-40 and then
washed twice more with PF buffer. The coverslips were incubated with primary
antibodies for one hour, washed 6× with PF buffer, incubated with secondary antibodies
(Alexa Fluor 546 anti-mouse or AlexaFluor 488 anti-mouse, Invitrogen) for one hour and
then washed 6× with PF buffer. Coverslips were mounted onto glass slides with ~10 μL
of Vectashield mounting media with DAPI (Vector Laboratories) and then sealed with
nail polish. Slides were examined using a Zeiss LSM 510 confocal fluorescence
microscope and images were obtained with sequential imaging.
2.8

Molecular Modelling
Three-dimensional models of the B30.2 domain from each TRIM22 isoform were

built based on homologues of known structures using the web-based server 3D-JIGSAW,
version 2.0 (http://bmm.cancerresearchuk.org/~3djigsaw/) [188, 189] using the following
query

sequences:

TRIM22α

(YWVDVMLNPGSATSNVAISVDQRQVKTVRTCTFKNSNPCDFSAFGVFGCQYFS
SGKYYWEVDVSGKIAWILGVHSKISSLNKRKSSGFAFDPSVNYSKVYSRYRPQY
GYWVIGLQNTCEYNAFEDSSSSDPKVLTLFMAVPPCRIGVFLDYEAGIVSFFNVT
NHGALIYKFSGCRFSRPAYPYFNPWNCLVPMTVCPPSS);

and

TRIM22β
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(YWVDVMLNPGSATSNVAISVDQRQVKTVRTCTFKNSNPCDFSAFGVFGCQYFS
SGKYYWEVDVSGKIAWILGVHSKISSLNKRKSSGFAFDPSVNYSKVYSRYRPQY
GYWVIGLQNTCEYNAFEDSSSSDPKVLTLFMAVPPCRIGVFLDYEAGIVSFFNVT
NHGALIYKFSGCRFSRPAYPYFNPWNCLVPMTVCPPSS). Models were visualized
using the program Visual Molecular Dynamics (VMD), version 1.9, developed by the
Theoretical and Computational Biophysics Group at the Beckman Institute for Advanced
Science and Technology of the University of Illinois at Urbana-Champaign [190], using
the MultiSeq extension.
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CHAPTER 3: RESULTS
3.1

Summary of the general biological characteristics of the current published
TRIM22 isoforms
There are currently 36 known SNPs in the trim22 gene, including multiple

frameshift or nonsense mutations that result in the production of different truncated
isoforms of TRIM22 (Table 1). There are currently 19 publications characterizing the
biological function of TRIM22; however, not a single report has suitably discussed the
potential impact that SNPs may have on these findings. Furthermore, the TRIM22 field
appears to relate all biological functions identified to a single TRIM22 isoform. In an
attempt to associate known TRIM22 functions with specific trim22 SNPs, I mined the
literature to identify which TRIM22 isoforms have previously been reported. At least 4
different isoforms of TRIM22 have been studied (Figure 4), and at least 5 additional
trim22 clones have been developed without recorded nucleotide sequences (Table 2).
Retrospective analysis has revealed that the first identified trim22 clone
(accession number X82200) [121] was derived from an mRNA splice variant with a 4
amino acid deletion in the coiled-coil domain. In addition, this gene, cloned from the
Daudi cell line, appears to contain a single nucleotide deletion resulting in the production
of a premature stop codon, and subsequently a 52 amino acid truncation of the Cterminus. This 442 amino acid protein was suggested to restrict transcription from the
HIV-1 LTR, however no further investigation was performed [121]. Although no
accession numbers are given, it appears that this clone has been used in 4 additional
studies (Table 2), including a 2006 study that demonstrated TRIM22 can restrict HIV-1
replication in monocyte-derived macrophages [172].
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Table 1: Summary of known single nucleotide polymorphisms (SNPs) in the trim22
gene.
Nucleotide
Position

Codon
Position

Amino Acid
Position

140

2

47

182

2

61

206

2

69

268

1

90

300

3

100

313

1

105

318

3

106

372

3

124

463

1

155

510

3

170

537

3

179

624

3

208

642

3

214

694

1

232

725

2

242

731

2

244

763

1

255

790

1

264

836

2

279

Type of Mutation
Missense
Contig reference
Missense
Contig reference
Missense
Contig reference
Missense
Contig reference
Synonymous
Contig reference
Missense
Contig reference
Synonymous
Contig reference
Synonymous
Contig reference
Missense
Contig reference
Synonymous
Contig reference
Frameshift (Insertion)
Contig reference
Synonymous
Contig reference
Synonymous
Contig reference
Missense
Contig reference
Missense
Contig reference
Missense
Contig reference
Missense
Contig reference
Missense
Synonymous
Contig reference
Missense
Contig reference

SNP
Allele

Resulting
Amino Acid

A
T
A
C
A
G
A
G
C
T
A
C
T
C
G
A
A
G
T
C
G

Glu [E]
Val [V]
Asn [N]
Thr [T]
Gln [Q]
Arg [R]
Lys [K]
Glu [E]
His [H]
His [H]
Lys [K]
Gln [Q]
Ile [I]
Ile [I]
Glu [E]
Glu [E]
Asn [N]
Asp [D]
Thr [T]
Thr [T]
Glu [E]
Glu [E]
Gly [G]
Gly [G]
Asp [D]
Asp [D]
Ala [A]
Thr [T]
Thr [T]
Arg [R]
Leu [L]
Ser [S]
Ile [I]
Val [V]
Met [M]
Leu [L]
Leu [L]
Gln [Q]
Arg [R]

C
T
C
T
G
A
C
G
T
C
A
G
A
C
T
A
G
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Nucleotide
Position

Codon
Position

Amino Acid
Position

881

2

294

913

1

305

936

3

312

962

2

321

980

2

327

1035

3

345

1056

3

352

1092

3

364

1134

3

378

1203

3

401

1244

2

415

1316

2

439

1320

3

440

1324

1

442

1364

2

455

1414

1

472

1473

3

491

Type of Mutation
Missense
Contig reference
Synonymous
Contig reference
Synonymous
Contig reference
Missense
Contig reference
Missense
Missense
Contig reference
Synonymous
Contig reference
Synonymous
Contig reference
Missense
Contig reference
Synonymous
Contig reference
Synonymous
Contig reference
Missense
Contig reference
Frameshift (Deletion)
Contig reference
Frameshift (Insertion)
Contig reference
Missense
Contig reference
Nonsense
Contig reference
Missense
Contig reference
Missense
Contig reference

SNP
Allele

Resulting
Amino Acid

A
C
T
C
A
G
A
G
A
T
G
T
C
A
G
T
G
T
G
C
T
T
C

Lys [K]
Thr [T]
Leu [L]
Leu [L]
Ser [S]
Ser [S]
Lys [K]
Arg [R]
His [H]
Leu [L]
Arg [R]
Phe [F]
Phe [F]
Ser [S]
Ser [S]
Asn [N]
Lys [K]
Leu [L]
Leu [L]
Tyr [Y]
Tyr [Y]
Ile [I]
Thr [T]
Leu [L]
Pro [P]
Pro [P]
Pro [P]
Cys [C]
Arg [R]
Stop [X]
Ser [S]
Ser [S]
Cys [C]
Ile [I]
Met [M]

C
C
T
C
A
C
A
T
A
G
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Table 2: Summary of trim22 clones used in literature.
Accession
Number

First
Published

X82200

1995

BC035582 c

2002

N/A

2006

NM_006074

2007

N/A

2008

N/A d

2008

N/A

2009

HQ_842635

2011

N/A

2011

a

Length
(bp; aa)
1329;
442

1497;
498
N/A
1497;
498
N/A

Reported Source

cDNA from human placenta
Open Biosystems

SNP at NT 642; Synonymous

[197]

CDS from human PBMCs

Sequence unknown.
a) Splice variant:
- Missing NT 519-531; AA 174-177
b) SNP at NT 725; R-->T (AA 242)
c) Primers based off X82200:
- No SNP at NT 1316, therefore
no stop codon at NT 1326
- NT 1330-1347 from pcDNA3.1 backbone
- Unique C-term ("ARACI")
Sequence unknown.
a) SNP at NT 463; D-->N (AA 155)
b) SNP at NT 725; R-->T (AA 242)

[130, 132, 198]

Sequence unknown.

[144]

cDNA from Daudi cell line

cDNA from testis

Coding region subcloned from
X82200 e

N/A
1497;
498

cDNA sequence
Gene from U937 nonpermissive
cells
CDS from monocyte-derived
dendritic cells/macrophages f

Variations listed in relation to the BC035582 reference sequence.
Due to no accession number listed, use is only suspected in some references listed, based on publication year and source listed as N. Mechti.
c
Denoted as TRIM22β throughout this thesis.
d
Denoted as TRIM22α throughout this thesis.
e
Reported source may not be accurate, due to lack of SNP at nucleotide 1316.
f
Cells were stimulated with IFNβ and lipopolysaccharide.
b

Reported Use b
(By reference)

a) Splice variant:
- Missing NT 519-531 (AA 174-177)
b) SNP at NT 725 (AA 242); R-->T
c) SNP at NT 1316; Deletion
- Premature stop codon at NT 1326
- Unique C-term ("LPVVLGFS")
Available through Open Biosystems:
TRIM22-pCMV-SPORT6 (ID: 5583800)
Sequence unknown.

1347;
448

N/A

Notes/Unique Features a

[105, 121, 125, 131,
135]

[144, 146, 191-194]
[195, 196]

[134]

[199]
[144]
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In 2008, Barr, et al. observed that a similarly truncated, 448 amino acid TRIM22
protein (from here referred to as TRIM22α) (Figure 4) (Table 2) was also capable of
restricting HIV-1 replication. In contrast to the effects on transcription observed by Tissot
and Mechti (1995), TRIM22α was shown to interfere with Gag trafficking to the plasma
membrane of HOS cells [134]. Furthermore, TRIM22α was observed to restrict HIV-1
replication in multiple cell lines. Of note, intracellular Gag levels in the HOS and HeLa
cell lines appeared unaffected by TRIM22α expression, yet were dramatically reduced in
the U2OS and 143b cell lines, suggesting that certain TRIM22 functions may be cell-type
specific [134].
A full-length (498 amino acid) protein was more recently reported to also block
HIV-1 replication and LTR-mediated transcription [144]. However, a deeper look into
the TRIM22 clones used revealed that this study used three different clones throughout
the study, at least two of which contain unique SNPs (Table 2). One clone, which had
been described in earlier studies, is a 498 amino acid protein, with a nucleotide sequence
matching the trim22 consensus sequence (BC035582, from here referred to as
TRIM22β). In addition, a novel clone was created from the trim22 gene in nonpermissive U937 cells, for which the sequence is published (HQ_842635). Although the
new clone is also 498 amino acid in length, it contains SNPs at nucleotides 463 and 725,
which result in amino acid substitutions at positions 155 and 242, respective to
TRIM22β. A third trim22 coding sequence was also cloned from a mix of stimulated
monocyte-derived macrophages and dendritic cells, for which no sequence is provided.
Furthermore, it is somewhat unclear which trim22 clones are used for which experiments,
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resulting in additional uncertainty surrounding the potential effects of SNPs on TRIM22
function.
It appears that at least three other trim22 clones have been independently
produced and used for various studies (Table 2). No sequences have been published for
these clones, nor have any accession numbers been given. In addition, several other
groups have studied TRIM22 during in vivo studies without any indication of which
isoform was studied. As a result, it is unclear which TRIM22 isoforms are associated
with which biological functions of TRIM22. Taken together, these findings show that a
number of different TRIM22 isoforms have been used in the literature, and multiple
isoforms have been shown to restrict HIV-1 replication.
3.2

The TRIM22α and TRMI22β isoforms exhibit different patterns of
localization
According to published reports, the subcellular localization of TRIM22 appears to

be variable and dynamic. Some reports show TRIM22 to be cytoplasmic [105, 199],
whereas others show it to be nuclear [130, 132, 193, 198] or both [144, 191, 192, 197]
(Table 3). Furthermore, TRIM22 has been shown to localize to Cajal bodies [191], the
centrosome, or vimentin containing aggresome-like structures next to the endoplasmic
reticulum [192]. These reports do not discuss the discrepancies observed between the
various TRIM22 localization patterns. Possible explanations for these observed
discrepancies in subcellular localization include cell type differences, endogenous versus
exogenous expression of TRIM22, different TRIM22 isoforms (long versus short), and
genetic variability in the TRIM22 isoforms studied (SNPs).
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Table 3: Summary of the localization patterns observed for TRIM22 in literature.
Localization

Pattern

Cell Type

Epitope Tag

Reference

Cytoplasm

Diffuse

293T

GFP or V5/His

[199]

Diffuse

COS7

GFP or V5/His

[199]

Diffuse

HeLa

Endogenous

[199]

Diffuse with speckles/bodies

HeLa

GFP

[105]

Diffuse

HeLa

GFP or V5/His

[199]

Diffuse

PBMCs

Endogenous

[199]

Diffuse with speckles/bodies
Nucleoplasmic, with nuclear
bodies1
Nuclear and cytoplasmic bodies
Diffuse throughout, or nuclear
bodies2
Nucleoplasmic, with nuclear
bodies
Diffuse, with cytoplasmic bodies3

U2OS

GFP

[105]

ABC28

Endogenous

[191]

293T

HA

[144] 7

HeLa

EGFP

[191] 7

HeLa

Endogenous

[191]

HeLa

[197]

Nucleoplasmic with NB4

MCF7

FLAG
EGFP, EYFP, or
FLAG

MCF7

Endogenous

[191]

T47D

Endogenous

[191]

U2OS

Endogenous

[192]

Aggregates/bodies

293T

Myc

[130]

Aggregates/bodies

COS7

Myc

[198]

Diffuse with speckles/bodies

HepG2

Endogenous

[132]

Diffuse with speckles/bodies

HepG2

Myc

[132]

Diffuse with bodies

MCF7

FLAG

[193] 7

Cytoplasm &
Nucleus

Nucleoplasmic, with nuclear
bodies
Nucleoplasmic and cytoplasmic
Diffuse with speckles
Nucleus

1

5,6

[191] 7

Some co-localization with fibrillarin (Nucleoli).
Pattern changes with cell cycle phase;
(G0/G1 = Nuclear Bodies; S-Phase = Nuclear speckles & cytoplasmic; Mitosis = Diffuse throughout cell).
3
TRIM22 plasmid was co-expressed with Rhesus TRIM5α.
4
Partial co-localization with Cajal bodies.
5
Potential co-localization with calnexin (Endoplasmic reticulum).
6
Partial co-localization with the centrosome.
7
Same clone as TRIM22β isoform.
2
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To determine if the localization of endogenous TRIM22 varied between cell
types, several cell lines were treated with IFNβ to induce TRIM22 expression and
analyzed by confocal immunofluorescence microscopy (Figure 5). Cells were harvested
24 h later, and expression was detected using a TRIM22 monoclonal antibody.
Interestingly, TRIM22 exhibited a variety of localization patterns, depending on the cell
type observed. In the U2OS, HOS, 293T, and HeLa cell lines, TRIM22 localized
primarily in the nucleus in a diffuse to punctate pattern, however some TRIM22 also
localized in the cytoplasm (Figure 5a). In the T cell lines Jurkat E6.1 and H9, TRIM22
localized in a diffuse to punctuate pattern throughout the cytoplasm (Figure 5b). PBMCs
from two different donors were isolated and treated with IFNβ to induce TRIM22
expression. Interestingly, TRIM22 localized exclusively in clusters in the nucleus of cells
from one donor, whereas in the second donor, TRIM22 localized predominantly in the
cytoplasm (Figure 5c).
To eliminate potential cell-type differences, which may in turn impact TRIM22
function and localization, a single cell line was chosen to study the TRIM22α and
TRIM22β isoforms. U2OS cells were chosen based on previous observations by Barr, et
al. demonstrating that TRIM22α expression not only restricted release of HIV-1 from
U2OS cells, but also resulted in decreased levels of intracellular Gag. Conversely,
TRIM22α expression in HOS cells was only capable of restricting release of HIV-1, and
had no effect on intracellular Gag levels. This is particularly interesting because it was
observed that TRIM22α expression resulted in altered Gag trafficking in HOS cells, but
no mechanism was ever investigated in U2OS cells [134]. As TRIM22β expression has
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Figure 5: Subcellular localization of endogenous TRIM22 in multiple cell lines.
All cells were treated with 500 U/ml of recombinant IFN-β overnight to induce TRIM22
expression. Cells were fixed and stained with mouse anti-human TRIM22 antibody, and
with secondary anti-mouse AlexaFluor 488 or AlexaFluor 546. A) TRIM22 primarily
localized to the nucleus of several non-lymphoid cell lines (U2OS, 293T, HeLa, HOS).
B) TRIM22 primarily localized to the cytoplasm of the T-cell lines (Jurkat E6.1, H9). C)
TRIM22 exhibited different patterns of localization in PBMCs from two different donors.
In donor 1, TRIM22 primarily localized to the cytoplasm in a diffuse/punctate pattern,
whereas in donor 2, TRIM22 primarily localized to the nucleus and appeared to organize
into nuclear bodies.
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been shown to block transcription from the HIV-1 LTR [144], we sought to determine
which mechanism of action was active in U2OS cells.
To determine the localization of TRIM22α and TRIM22β, plasmids encoding
each isoform with an N-terminal FLAG-tag were individually transfected into U2OS
cells. Cells were harvested 24 hours after transfection, stained with FLAG antibodies, and
analyzed using confocal immunofluorescence microscopy (Figure 6). We observed that
TRIM22α localized predominantly in the cytoplasm, and exhibited a diffuse pattern of
localization. Conversely, TRIM22β localized predominantly in the nucleus and often
appeared to localize in clusters. Taken together, these findings reveal that TRIM22
exhibits a range of localization patterns, which is likely influenced by several factors. It
appears that differences in cell lines, cell types, TRIM22 isoforms, genetics, and
endogenous vs. exogenous expression may play a role in determining the localization of
TRIM22.
3.3

The B30.2/SPRY domain of TRIM22β is important for nuclear localization
Given that the nuclear TRIM22β isoform has a B30.2 domain that is 50 amino

acids longer than the cytoplasmic TRIM22α isoform, we hypothesized that this domain
helps dictate the subcellular localization of TRIM22. To determine if the B30.2/SPRY
domain is required for nuclear localization, a plasmid encoding a FLAG-tagged
TRIM22β isoform with the B30.2/SPRY domain deleted (TRIM22β-ΔSPRY, previously
made in our laboratory) was transfected into U2OS cells and analyzed using confocal
immunofluorescence microscopy (Figure 6). We observed that deletion of the
B30.2/SPRY domain abolished the nuclear localization of TRIM22β, resulting in a
diffuse cytoplasmic pattern that closely resembled the localization pattern of TRIM22α.
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Figure 6: Subcellular localization of different TRIM22 isoforms in U2OS cells.
U2OS cells were transfected with plasmids encoding one of the TRIM22 isoforms.
Twenty-four hours post-transfection, cells were fixed and stained with mouse anti-FLAG
antibody, and with secondary anti-mouse AlexaFluor 488. TRIM22α exhibited diffuse
localization throughout the cytoplasm, whereas TRIM22β predominantly localized to the
nucleus in a nuclear body pattern. Deletion of the B30.2 domain of TRIM22β abolished
body formation and nuclear localization.
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In addition, multiple reports have noted similar findings [132, 193, 199], supporting the
conclusion that the B30.2/SPRY domain is required for the nuclear localization of
TRIM22β.
It has been previously reported that the Spacer 2 domain of TRIM22 contains a
predicted bi-partite nuclear localization signal (NLS) at amino acids 265 to 269 [121]
(Figure 4). Conversely, there are no predicted NLS consensus sequences in the B30.2
domain; however, a KRK sequence is present at amino acid 380 (Figure 4). While this
does not match the Lys-Arg/Lys-X-Arg/Lys consensus NLS sequence described by
Chelsky, et al. [200], other groups have shown that the KRK sequence is sufficient to
direct nuclear localization of several proteins, such as SHP-1 [201, 202]. As a result, we
hypothesized that the presence of amino acid substitutions and/or deletions in the B30.2
domain may alter its structure and hide this KRK sequence, resulting in altered
localization patterns.
Although the crystal structure of TRIM22 is yet to be solved, molecular modeling
of the B30.2 domain from TRIM22α/β was performed using the programs 3D-JIGSAW
and Visual Molecular Dynamics (Figure 7). The TRIM22α and TRIM22β B30.2 domain
models were assigned accuracy scores of 5.40 and 5.69, respectively, indicating over
95% probability that the query and template sequences alignments are accurate. Although
the position of the KRK sequence is not directly affected by the truncation, we did note
the appearance of a large pocket in the TRIM22α B30.2 domain that is partially filled by
the additional amino acids present in TRIM22β (Figure 7a). In addition, the TRIM22β
B30.2 domain contains four anti-parallel β-sheets, two of which are lost in the TRIM22α
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Figure 7: Molecular modelling of the B30.2 domain from different TRIM22
isoforms.
Molecular modelling was used to predict the structure of the B30.2 domain from different
TRIM22 isoforms. The B30.2 domain from TRIM22α is depicted in orange, and that
from TRIM22β is depicted in blue. The KRK NLS sequence is highlighted in red. The
overlay frames illustrate the TRIM22α B30.2 domain with the C-terminal 50 amino acids
from TRIM22β overlaid in green to accentuate the differences between the two isoforms.
A) A large pocket is visible in the TRIM22α B30.2 domain that is partially filled by the
additional amino acids possessed by TRIM22β, as indicated by the white arrow. B) A
plane of four anti-parallel β-sheets present in the TRIM22β B30.2 domain is disrupted in
the TRIM22α structure, as indicated by the white arrow.
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structure (Figure 7b). While it is clear that B30.2 domain is important, the role that these
features play in controlling localization requires further investigation.
3.4

The TRIM22α and TRIM22β isoforms possess different degrees of HIV-1
restriction in the same cell type
Although different short and long TRIM22 isoforms have independently been

shown to restrict HIV-1 replication in vitro [131, 134, 144, 145], the degree to which
these isoforms restrict HIV-1 in comparison to each other is unknown. To determine and
compare the restriction capabilities of TRIM22α and TRIM22β in vitro, we performed
HIV-1 release assays. In brief, plasmids encoding a TRIM22 isoform (or empty vector
control) and a replication-competent HIV-1 provirus (pR9) were co-transfected into
either HOS-CD4/CXCR4 or U2OS cells. After 48 hours, supernatants containing virus
were collected, clarified via low-speed centrifugation, and used to infect the HIV reporter
cell line GHOST (3) X4/R5. This reporter cell line supports HIV-1 replication and
contains a green fluorescent protein (GFP) construct under the transcriptional control of
the HIV-2 LTR promoter, thus cells that become infected will express GFP. Infections
were allowed to proceed for 48 hours, after which the level of infection was quantified by
determining the percentage of GFP-expressing cells using flow cytometry.
As shown in Figure 8, both TRIM22 isoforms substantially inhibited the release of
infectious HIV-1 particles from HOS-CD4/CXCR4 cells and U2OS cells. HOSCD4/CXCR4 cells expressing the TRIM22α isoform exhibited a 1.3-fold reduction in
virus release, whereas the TRIM22β isoform resulted in a 2.8-fold reduction in virus
release, compared to cells transfected with a vector control. Notably, the effects of both
isoforms appeared to be much more potent in U2OS cells. Expression of TRIM22α and
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Figure 8: The TRIM22α and TRIM22β isoforms vary in their ability to restrict
release of infectious HIV-1 particles.
HOS-CD4/CXCR4 and U2OS cells were co-transfected with plasmids encoding a
replication-competent HIV-1 provirus (pR9), and TRIM22α, TRIM22β, or the control
empty expression vector pGL3. Virus supernatants were collected 48 hours posttransfection, and used to infect the reporter cell line GHOST(3) X4/R5. Infection was
allowed to proceed for 48 hours, after which GHOST(3) X4/R5 cells were harvested,
fixed, and analyzed for GFP expression by flow cytometry. Results (percentage of cells
fluorescing) are presented as fold difference compared to the pGL3 vector control, and
represent the amount of infectious virus released from the transfected HOS-CD4/CXCR4
and U2OS cells.
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TRIM22β in U2OS cells resulted in approximately a 10-fold and 20-fold reduction in
virus release, respectively, compared to cells transfected with a vector control. Taken
together, these data show that TRIM22α and TRIM22β both effectively inhibit release of
infectious HIV-1 particles; however the actions mediated by TRIM22β appear to be more
dominant.
3.5

The TRIM22α and TRIM22β isoforms restrict transcription from viral
promoters to varying degrees
Previous reports have shown that TRIM22α alter trafficking of the Gag

polyprotein to the plasma membrane [134], and TRIM22β can inhibit transcription from
the HIV-1 LTR [144]. Interestingly, TRIM22α also prevents the accumulation of
intracellular Gag polyprotein when co-expressed with an HIV-1 provirus in U2OS cells
[134], suggesting it may also block LTR-mediated transcription. We therefore sought to
compare the ability of the TRIM22α and TRIM22β isoforms to block HIV-1 LTR
transcription during a productive infection in vitro. Plasmids encoding a TRIM22 isoform
(or empty vector control) and a replication-competent HIV-1 provirus (pR9) were cotransfected into U2OS cells. Cells were harvested 48 hours post-transfection and total
mRNA was harvested and reverse transcribed using poly d(T) primers. HIV-1 LTR
transcription was assessed via quantitative real-time PCR (qPCR) using primers specific
to a region of the HIV-1 gag gene. The β-actin gene was amplified as a loading control,
and CT values for gag were normalized to β-actin levels prior to analysis. We observed
that both TRIM22α and TRIM22β inhibited transcription from the HIV-1 LTR, resulting
in approximately a 3-fold and 20-fold reduction in gag cDNA levels, respectively,
compared to cells transfected with a vector control (Figure 9a).
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Figure 9: The TRIM22α and TRIM22β isoforms vary in their ability to restrict
transcription from viral promoters.
U2OS cells were co-transfected with plasmids encoding TRIM22α, TRIM22β, or the
control empty expression vector pGL3, and (A) a replication-competent HIV-1 provirus
(pR9) or (B) a plasmid encoding Gag under the control of the CMV promoter (pGag-opt).
Total cellular mRNA was reverse transcribed and cDNA was analyzed by quantitative
real-time PCR (qPCR) using primers specific to a region of the gag gene, and primers
amplifying β-actin as a loading control. Results were normalized to β-actin levels, and are
expressed as relative fold change in expression compared to the pGL3 vector control.
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To determine if these effects on transcription were unique to the HIV-1 LTR, the
experiment was repeated using a plasmid encoding a codon optimised Gag polyprotein
under control of a CMV promoter (pGag-opt), instead of an HIV-1 provirus. TRIM22α
and TRIM22β inhibited transcription from the CMV promoter in a similar manner to the
LTR, resulting in approximately a 2-fold and 11-fold reduction in gag cDNA levels,
respectively, compared to cells transfected with a vector control (Figure 9b). To confirm
this effect at the protein level, the TRIM22/pGag-opt co-transfection was repeated, and
samples were harvested 48 hours post-transfection. Clarified supernatants were
centrifuged over a sucrose cushion to pellet Gag VLP, and a western blot was performed
on the cell lysate and supernatant fractions (Figure 10). Densitometric quantification
revealed that TRIM22α and TRIM22β reduced the amount of intracellular Gag by
approximately 1.76-fold and 1.57-fold, respectively, in addition to restricting the amount
of Gag VLP released by 1.75-fold and 1.51-fold, respectively.
3.6

Several commonly used cell lines are negative for an SNP insertion in the
trim22 gene

The level of impact that SNPs have on controlling HIV-1 infection is yet to be
determined; however, it is clear that they are an important contributing factor [175]. This
concept is easily observed in individuals homozygous for the CCR5/Δ32 mutation, which
confers robust resistance to HIV-1 infection [4-6]. Polymorphisms in host innate
immunity genes that inhibit HIV-1 replication have also been shown to impact HIV-1
infection and disease progression. For example, certain SNP profiles for the APOBEC3H
gene have been shown to not only affect the stability and subcellular localization of A3H,
but also its capacity to restrict HIV-1 replication [179-181] and slow disease progression
[182]. Recent observations have shown that trim22 expression may be associated with

54

Figure 10: The TRIM22α and TRIM22β isoforms block release of HIV-1 Gag-only
particles.
U2OS cells were co-transfected with plasmids encoding TRIM22α, TRIM22β, or the
control empty expression vector pGL3, and a plasmid encoding Gag under the control of
the CMV promoter (pGag-opt). Cells and supernatants were harvested 48 hours posttransfection, and Gag particles were pelleted by centrifugation. A western blot was
performed on the cell and supernatant fractions using p24CA (anti-Gag) antibodies.
Densitometric analysis was performed using ImageJ software, and is indicated by the
numbers.
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viral control during primary HIV-1 infection [145]. In addition, we have shown here that
the localization patterns and potency of antiviral activity appear to vary between TRIM22
isoforms. The TRIM22α isoform localized to the cytoplasm and exhibited less antiviral
activity than the nuclear localized TRIM22β. These isoforms may also possess different
antiviral mechanisms, as demonstrated by the potent transcriptional repression exhibited
by TRIM22β (Figure 9), and the ability for TRIM22α to alter trafficking of the HIV-1
Gag protein [134].
Although the TRIM22α isoform is not the direct result of an SNP, at least 3
trim22 SNPs result in the production of isoforms very similar to TRIM22α. As similar
sized TRIM22 isoforms likely have similar characteristics, we were interested in
determining if any of these SNPs are present in the trim22 gene from several commonly
used cell lines. Due to financial constraints, we were only able to investigate a single
SNP at the time of this study. We chose to determine the allele located at NT position
1320, as this position is subject to a known SNP insertion, resulting in a frameshift
mutation, and subsequently the creation of a premature stop codon. The corresponding
truncated protein is of similar length and sequence to the TRIM22α protein used in our
studies, thus this SNP holds interesting implications for the localization and function of
endogenous TRIM22 observed in these cell lines. Genomic DNA was first extracted from
each cell line, the full B30.2 domain was amplified for each sample, and all samples were
sent for SNaPshot PCR analysis. This technique is a quick and economical approach to
rapidly identify specific SNPs of interest (see Methods for details). As seen in Table 4, all
samples were identified to contain the consensus allele, indicating that they do not
contain an insertion at position 1320. It will be important to investigate the presence of
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other SNPs in these genes, as a frameshift mutation at position 1316, as well as a
nonsense mutation at position 1364, also result in similarly sized TRIM22 isoforms.
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Table 4: List of alleles present at nucleotide 1320 in commonly used cell lines, as
reported by SNaPshot PCR.

Cell Line

Allele

143b

A

293T

A

CEM-SS

A

HeLa

A

HOS

A

Jurkat

A

THP-1

A

U2OS

A

U937

A
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CHAPTER 4: DISCUSSION
The data detailed in this thesis clearly show that a short and a long TRIM22
isoform

(TRIM22α

and

TRIM22β,

respectively)

possess

different

biological

characteristics and antiviral capabilities. We have observed that these isoforms possess
different patterns of localization, which molecular modelling suggests may be due to a
change in the structure of the B30.2/SPRY domain. Although both isoforms have
independently been reported to restrict HIV-1 replication [134, 144], this is the first direct
comparison of two TRIM22 isoforms. Furthermore, we have shown that these isoforms
exhibit different degrees of HIV-1 restriction, which is, at least in part, due to inhibition
of transcription from the 5‟ LTR. Nevertheless, this transcriptional block is not specific to
the HIV-1 LTR, as both isoforms were also capable of restricting transcription from the
CMV promoter.
Several complications arise when studying TRIM22 due to i) contradictory
reports on biological function, ii) potential cell type differences, iii) the existence of
numerous reported SNPs in the trim22 gene, and iv) the failure to identify the specific
TRIM22 isoform used in certain published studies. To better understand the potential
impact of trim22 SNPs, we mined the literature and summarized the information
currently known about TRIM22 functions. We have presented a list of 36 known SNPs in
the trim22 gene (Table 1). This list includes 4 SNPs known to result in the production of
premature stop codons, and thus shorter TRIM22 proteins, similar to the TRIM22α
isoform used in this study. We have also shown that no fewer than four unique TRIM22
isoforms have been used in past literature, along with at least four additional trim22
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clones for which no sequence information has been published (Table 2). Taken together,
these data help to highlight the importance of studying the effects of trim22 SNPs and
demonstrate that different TRIM22 isoforms possess varying degrees of activity.
The importance of reporting SNPs/isoforms is abundantly clear in the case of
APOBEC3H, as its stability, localization and ability to restrict HIV-1 replication and
slow disease progression have all been linked to SNPs [179-182]. While we are only
beginning to uncover the impact that SNPs may have on TRIM22 function, the recent
observation that trim22 expression may be associated with viral control during primary
HIV-1 infection [145] stresses the importance of proper documentation and
understanding of trim22 SNPs in the literature. Here we used SNaPshot PCR to show that
several commonly used cell lines are negative for a single nucleotide insertion at position
1320, which is one of the SNPs resulting in a TRIM22 truncation. Unfortunately due to
financial constraints, we have been unable to investigate any other SNPs in the trim22
gene; however, an alternative project in our laboratory will be using this approach to
investigate a number of SNPs in the trim22 gene from primary donors.
While the biological impact of trim22 SNPs is still largely unknown, there is no
doubt that some of the variation between TRIM22 reports is a result of different isoforms
being studied. This point is highlighted by the fact that TRIM22α and TRIM22β have
been previously shown to restrict HIV-1 replication by separate mechanisms [134, 144],
and several reports have observed a range of different localization patterns for TRIM22
(Table 3). In addition, numerous studies have investigated the functions of endogenous
TRIM22 in different samples/cell lines with unsequenced trim22 genes. Unfortunately,
without information about the possible SNPs or isoforms present, we are unable to fully
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associate and compare these findings to other information known about TRIM22 in the
literature.
Several other factors have also been suggested to affect the localization of
TRIM22, including cell type, method of fixation, and the epitope tag used for detection.
To gain further insight into these factors, we began by investigating the localization
pattern of IFNβ-induced endogenous TRIM22 in several common cell lines (Figure 5).
Interestingly, endogenous TRIM22 was primarily localized to the nucleus in several nonlymphoid cell lines (HOS, U2OS, HeLa, 293T), compared to the predominantly
cytoplasmic localization in two T-cell lines (Jurkat E6.1, H9), suggesting that cell type
differences may be a factor contributing to localization. Similar localization patterns have
previously been described for IFN-induced TRIM22 expression in U2OS and HeLa cells
[191, 192]; however another report found endogenous TRIM22 to only be present in the
cytoplasm of HeLa cells [199]. Nevertheless, this report did not appear to induce
TRIM22 expression by any means, which may account for the observed differences. In
contrast, IFNβ-treated PBMCs isolated from two different donors exhibited contrasting
patterns of localization (Figure 5c), suggesting that host genetics may also impact the
biological characteristics of TRIM22.
To further explore the potential effects of trim22 SNPs on localization pattern,
U2OS cells were used to investigate two different TRIM22 isoforms previously described
in the literature. We observed that our TRIM22α isoform, which contains a 50 amino acid
truncation of the B30.2 domain, exhibited a predominantly diffuse pattern throughout the
cytoplasm (Figure 6). Although many of the reports on TRIM22 localization have no
sequence information available, a similar short form (X82200) was also observed to
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localize predominantly to the cytoplasm of U2OS cells [105]. Interestingly, our fulllength isoform, TRIM22β, localized almost exclusively to the nucleus, and exhibited a
diffuse pattern with nuclear bodies (Figure 6).
We also observed that deletion of the B30.2 domain in TRIM22β resulted in a
localization pattern nearly identical to that of TRIM22α (Figure 6). This result was not
surprising, as multiple reports have also noted the importance of the B30.2 domain for
TRIM22 localization [132, 193, 199]. Molecular modeling of the B30.2 domain predicted
the presence of a large pocket (Figure 7a), as well as the loss of several β-sheets in the
TRIM22α model (Figure 7b), although the KRK NLS sequence remains in the same
position in both isoforms. It is possible that the TRIM22α truncation disrupts a binding
groove/interface in the B30.2 domain that is required for interaction with proteins which
dictate the localization of TRIM22. Nevertheless, as we are currently limited to modeling
programs, it is also possible that the loss of amino acids in the TRIM22α B30.2 domain
disrupts the stabilization of this domain, resulting in unfolding and complete loss of
structure. Regardless, it appears that the C-terminal 50 amino acids are required for
nuclear localization, thus it will be interesting to examine if the other 4 SNPs known to
exist in this region also have an impact on subcellular localization and potentially
function. Future experiments using more targeted mutations within the TRIM22β B30.2
domain will help to elucidate the specific amino acids determinants for nuclear
localization, and protein binding assays may be useful in discovering potential proteins
that interact with this domain.
Although TRIM22α and TRIM22β have both been shown to restrict HIV-1
replication [134, 144], this was performed in separate studies and different cell lines, thus
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it was important to directly compare the potency of their anti-HIV-1 activity in relation to
each other. We co-transfected HOS and U2OS cells with TRIM22/HIV-1 provirus, and
used the resulting viral supernatants to infect the GHOST(3) X4/R5 reporter cell line
(Figure 8). This provides a measurement of the infectious virus released, allowing a
direct comparison of antiviral activity, regardless of the mechanism of action. As a result,
this method holds an advantage over western blot, which measures total Gag protein, and
cannot discriminate between infectious and non-infectious material. Importantly,
expression of either isoform resulted in a dramatic decrease in the amount of virus
released, regardless of cell-type. Furthermore, TRIM22β mediated restriction of virus
release was approximately twice as effective as compared to TRIM22α, suggesting that
their relative antiviral activity may be consistent between cell lines.
Of note, the overall antiviral effect was much stronger in U2OS cells, suggesting
that certain cell line specific differences may affect TRIM22 function. Similarly, Barr, et
al. observed that TRIM22α expression in HOS cells had differential effects on
intracellular Gag levels during proviral replication in HOS and U2OS cells. While
intracellular Gag levels were unaffected by TRIM22α expression in HOS cells, they were
dramatically reduced in U2OS cells [134]. It is possible this difference in intracellular
Gag levels is merely a result of the reduced antiviral activity we observed in HOS cells,
which may reflect cell type differences, such as the abundance of unknown cofactors, or
an impact on some rate limiting step. On the other hand, we observed TRIM22α to
restrict LTR transcription in U2OS cells, whereas Barr, et al. showed that TRIM22α alter
trafficking of the Gag polyprotein in HOS cells. Therefore, it is possible that the
difference in overall antiviral activity observed between HOS and U2OS cells may be the
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result of separate mechanisms being utilized, which will provide an interesting avenue to
follow up in future experiments.
Both the TRIM22α and TRIM22β isoforms were capable of restricting
transcription from the HIV-1 LTR in U2OS cells (Figure 9a). Although TRIM22β and
the X82200 TRIM22 isoform have been shown to restrict LTR-mediated transcription in
293T and Daudi cells, respectively [121, 144], this is the first evidence that TRIM22α can
affect viral transcription. Interestingly, the effects on transcription are not unique to the
HIV-1 LTR, as both isoforms also showed potent restriction of the CMV promoter in
U2OS cells (Figure 9b). This result is in stark contrast to a previous report that observed
TRIM22β to have no effect on a luciferase reporter gene under control of a CMV
promoter in 293T cells [144]. An unknown TRIM22 isoform has also been shown to
inhibit the activity of the hepatitis B virus core promoter in the hepatocellular carcinoma
cell line HepG2, thus it is likely that TRIM22 is a broadly acting repressor of viral
transcription, and potentially targets similar features among several promoters. As a
result, we believe that the contradictory results obtained in U2OS and 293T cells may be
a result of certain cell-specific differences, as discussed above.
How TRIM22 restricts transcription from viral promoters is unknown but a
fascinating problem for further study. It is intriguing that both isoforms can effectively
repress transcription, despite the fact that TRIM22α is predominantly located in the
cytoplasm, and TRIM22β is predominantly nuclear. It is possible that the two isoforms
target the same protein/pathway or have entirely different targets, thus it will be
important to further investigate and characterize the mechanisms of action. While we
have yet to rule out that TRIM22 may also target HIV-1 RNA somehow, such as Rev-
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dependent RNA export, is important to note that the gag gene under control of the CMV
promoter is both codon-optimized and Rev-independent. Taken together with the ability
to restrict transcription from multiple viral promoters, it seems unlikely that RNA is a
primary target.
A recent report observed a significant decrease in LTR transcription was observed
in TRIM22β-expressing cells during stimulation with phorbol 12-myristate 13-acetate
(PMA) and ionomycin [144]. This stimulation activates the transcription factors AP-1
and NFAT [203, 204], which are both important cis-acting elements present in the
enhancer region of the HIV-1 LTR [12, 14]. Furthermore, AP-1 is important for optimal
transcription from the HBV [205] and CMV [206] promoters, and NFAT was recently
shown to be required for optimal reactivation of latent HIV-1 in CD4+ T cells [13]. One
candidate model would be that TRIM22 interferes with one or more of the transcription
factors required for optimal expression, such as AP-1 of NFAT. Furthermore, certain
transcription factors, such as NFAT, reside in the cytoplasm until activated, which may
explain why the cytoplasmic TRIM22α isoform is also capable of restricting
transcription. It will be useful to identify if either TRIM22 isoform is capable of
interacting with or altering the function of these transcription factors. PMA + ionomycin
stimulation is also known to result in chromatin remodelling in the 5′ LTR of bovine
leukemia virus [207], thus it is also possible that TRIM22 interferes with chromatin
organization surrounding the HIV-1 LTR of the integrated provirus.
It remains likely that different TRIM22 isoforms possess unique mechanisms of
restriction in addition to a common ability to repress LTR dependent transcription. It is
interesting to note that TRIM22β expression resulted in approximately twice the
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restriction of TRIM22α in the virus release assay (Figure 8), and even more so in the
qPCR assays (Figure 9); however, the two isoforms exhibited similar restriction profiles
for the pGag-opt western blot (Figure 10). Only TRIM22α has previously been shown to
alter Gag trafficking to the plasma membrane, thus it is possible TRIM22β possesses
stronger effects on transcription and TRIM22α activity is stronger at the protein level.
Surprisingly, TRIM22β restriction of the HIV-1 LTR was shown to be independent of its
E3 ligase activity [144]. As this activity has been shown to be important for other
TRIM22 antiviral activities, including restriction of the HBV core promoter [132, 134,
146], it will be interesting to determine if E3 ligase activity is required for the antiviral
activity that we observed. Additional studies will be useful to identify the mechanisms
employed by these two TRIM22 isoforms, and to provide further insight into the potential
impact of SNPs on TRIM22 functions.
4.1

Limitations of this study
One limitation to consider is that the majority of our experiments were primarily

performed in the U2OS cell line. There is strong evidence to suggest that TRIM22 may
possess different levels of activity or perform different actions, depending on which cell
line is being investigated. While we observed both isoforms to restrict transcription from
the HIV-1 LTR and CMV promoter in U2OS cells, previous studies observed TRIM22α
to alter trafficking of the Gag polyprotein [134], and TRIM22β did not restrict
transcription from the CMV promoter in 293T cells [144]. At this point it is unclear
which factors may contribute to these differences, thus it will be important to repeat these
experiments in additional cells lines. Furthermore, while these cell lines are useful study
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tools, they are not biologically relevant to HIV-1 infection. Future experiments should
include more relevant models, such as the Jurkat E6.1 T cell line or primary cells.
While there appears to be striking differences between the TRIM22α and
TRIM22β isoforms, this study was also limited by our use of only two TRIM22 isoforms.
A total of 36 SNPs are currently known to exist in the trim22 gene, including 21 missense
mutations, and 4 SNPs which result in different length proteins. Currently none of these
SNPs have been investigated, thus it will be important to examine additional isoforms to
better understand what effect these SNPs have on the functions of TRIM22. In addition,
due to financial limitations, we were only able to investigate the prevalence of one SNP
in a small number of cell lines; however, it will be essential to determine the prevalence
of these SNPs in the population.
4.2

Future directions
The present study demonstrated that two unique TRIM22 isoforms are capable of

restricting HIV-1 transcription and replication in the U2OS cell line. While we provided
the first evidence that the TRIM22α isoform can restrict viral transcription, TRIM22α has
previously been shown to alter Gag trafficking in HOS cells. Nevertheless, it is currently
unknown if TRIM22α can also alter Gag trafficking in U2OS cells, or restrict LTR
transcription in HOS cells. Determining which antiviral mechanisms are active in these
cell lines may help to elucidate additional factors required for TRIM22-mediated
restriction and explain the dramatic difference in antiviral potency between HOS and
U2OS cells.
In addition, all previous experiments demonstrating that TRIM22 can restrict LTR
transcription have been performed using components from HIV-1 subtype B viruses.
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While this is the best characterized form, subtype B only accounts for 12% of global
infections, and observations obtained with this subtype may not be transferrable to other
subtypes due to considerable differences in LTR composition, such as the number of
NFκB response elements [10, 16]. It will be important to determine the capacity of
TRIM22 to restrict transcription from the LTR of other HIV-1 subtypes. Furthermore,
TRIM22 has also been shown to restrict transcription from the hepatitis B virus core
promoter, thus it will be interesting to test the effect of TRIM22 on other viral promoters.
This will not only help determine the breadth of TRIM22 activity, but these experiments
may also help elucidate possible targets for TRIM22 based on common elements between
viral promoters.
In order to better understand the relationship between SNPs and TRIM22
function, it will also be important to identify the TRIM22 isoforms used in previous
studies, where possible, and to report all TRIM22 isoforms used in future experiments. It
will also be useful to develop and characterize a panel of TRIM22 isoforms to determine
which SNPs influence TRIM22 features, such as localization. Furthermore, experiments
examining the trim22 haplotypes of both healthy and infected individuals will help
determine the prevalence of each SNP and reveal any correlation between specific SNPs
and HIV-1 disease progression.

4.3

Conclusions
In general, the study of how our immune system responds to HIV-1 infection has

been a focus of researchers worldwide since AIDS was first recognized over 30 years
ago. Understanding how a small percentage of individuals are naturally capable of
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controlling HIV-1 replication remains one of the most sought after objectives towards the
development of more effective therapies. While the contribution of cellular restriction
factors in controlling HIV-1 infection is still controversial, evidence continues to build
suggesting they do play a role. Furthermore, the effect that SNPs have on HIV-1 disease
progression is becoming increasingly clear, and will be a necessary factor to consider in
future investigations.
Although findings on TRIM22 continue to suggest it is an important antiviral
protein capable of restricting HIV-1 replication, much work remains to be done in order
to fully ascertain how this protein functions. A balance between laboratory and clinical
studies will help to elucidate the mechanisms responsible for these antiviral actions, as
well as any potential effect TRIM22 may have on the progression of HIV-1 infection in
vivo. Regardless, routine reporting of the TRIM22 isoforms used, along with the
execution of studies directly comparing the actions of multiple isoforms will be a crucial
step towards better understanding how SNPs may impact the function of TRIM22.
Overall, increasing our knowledge of these host-pathogen interactions will allow for
increased understanding of HIV-1 pathogenesis and the continuation of breakthroughs in
HIV/AIDS treatment and prevention.
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APPENDICES
Appendix 1: Sequence information for the TRIM22α isoform.

NUCLEOTIDE [CODING SEQUENCE: 1347 bp]
atggatttctcagtaaaggtagacatagagaaggaggtgacctgccccatctgcctggagctcctgacagaacctctgagccta
gattgtggccacagcttctgccaagcctgcatcactgcaaagatcaaggagtcagtgatcatctcaagaggggaaagcagctgt
cctgtgtgtcagaccagattccagcctgggaacctccgacctaatcggcatctggccaacatagttgagagagtcaaagaggtc
aagatgagcccacaggaggggcagaagagagatgtctgtgagcaccatggaaaaaaactccagatcttctgtaaggaggatg
gaaaagtcatttgctgggtttgtgaactgtctcaggaacaccaaggtcaccaaacattccgcataaacgaggtggtcaaggaatg
tcaggaaaagctgcaggtagccctgcagaggctgataaaggaggatcaagaggctgagaagctggaagatgacatcagaca
agagagaaccgcctggaagatcgagagacagaagattctgaaagggttcaatgaaatgagagtcatcttggacaatgaggagc
agagagagctgcaaaagctggaggaaggtgaggtgaatgtgctggacaacctggcagcagctacagaccagctggtccagc
agaggcaggatgccagcacgctcatctcagatctccagcggaggttgacgggatcgtcagtagagatgctgcaggatgtgatt
gacgtcatgaaaaggagtgaaagctggacattgaagaagccaaaatctgtttccaagaaactaaagagtgtattccgagtacca
gatctgagtgggatgctgcaagttcttaaagagctgacagatgtccagtactactgggtggacgtgatgctgaatccaggcagtg
ccacttcgaatgttgctatttctgtggatcagagacaagtgaaaactgtacgcacctgcacatttaagaattcaaatccatgtgatttt
tctgcttttggtgtcttcggctgccaatatttctcttcggggaaatattactgggaagtagatgtgtctggaaagattgcctggatcct
gggcgtacacagtaaaataagtagtctgaataaaaggaagagctctgggtttgcttttgatccaagtgtaaattattcaaaagtttac
tccagatatagacctcaatatggctactgggttataggattacagaatacatgtgaatataatgcttttgaggactcctcctcttctgat
cccaaggttttgactctctttatggctgtgcctccctgtcgtattggggttttcctagctcgagcatgcatctag
PROTEIN (448 aa)
MDFSVKVDIEKEVTCPICLELLTEPLSLDCGHSFCQACITAKIKESVIISRGESSCPV
CQTRFQPGNLRPNRHLANIVERVKEVKMSPQEGQKRDVCEHHGKKLQIFCKEDG
KVICWVCELSQEHQGHQTFRINEVVKECQEKLQVALQRLIKEDQEAEKLEDDIR
QERTAWKIERQKILKGFNEMRVILDNEEQRELQKLEEGEVNVLDNLAAATDQLV
QQRQDASTLISDLQRRLTGSSVEMLQDVIDVMKRSESWTLKKPKSVSKKLKSVF
RVPDLSGMLQVLKELTDVQYYWVDVMLNPGSATSNVAISVDQRQVKTVRTCTF
KNSNPCDFSAFGVFGCQYFSSGKYYWEVDVSGKIAWILGVHSKISSLNKRKSSGF
AFDPSVNYSKVYSRYRPQYGYWVIGLQNTCEYNAFEDSSSSDPKVLTLFMAVPP
CRIGVFLARACI
NOTE
Underlined sequence is from the pcDNA3.1 plasmid.
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Appendix 2: Sequence information for the TRIM22β isoform.

ACCESSION BC035582
NUCLEOTIDE [CODING SEQUENCE: 1497 bp]
atggatttctcagtaaaggtagacatagagaaggaggtgacctgccccatctgcctggagctcctgacagaacctctgagccta
gattgtggccacagcttctgccaagcctgcatcactgcaaagatcaaggagtcagtgatcatctcaagaggggaaagcagctgt
cctgtgtgtcagaccagattccagcctgggaacctccgacctaatcggcatctggccaacatagttgagagagtcaaagaggtc
aagatgagcccacaggaggggcagaagagagatgtctgtgagcaccatggaaaaaaactccagatcttctgtaaggaggatg
gaaaagtcatttgctgggtttgtgaactgtctcaggaacaccaaggtcaccaaacattccgcataaacgaggtggtcaaggaatg
tcaggaaaagctgcaggtagccctgcagaggctgataaaggaggatcaagaggctgagaagctggaagatgacatcagaca
agagagaaccgcctggaagaattatatccagatcgagagacagaagattctgaaagggttcaatgaaatgagagtcatcttgga
caatgaggagcagagagagctgcaaaagctggaggaaggtgaggtgaatgtgctggacaacctggcagcagctacagacca
gctggtccagcagaggcaggatgccagcacgctcatctcagatctccagcggaggttgaggggatcgtcagtagagatgctgc
aggatgtgattgacgtcatgaaaaggagtgaaagctggacattgaagaagccaaaatctgtttccaagaaactaaagagtgtatt
ccgagtaccagatctgagtgggatgctgcaagttcttaaagagctgacagatgtccagtactactgggtggacgtgatgctgaat
ccaggcagtgccacttcgaatgttgctatttctgtggatcagagacaagtgaaaactgtacgcacctgcacatttaagaattcaaat
ccatgtgatttttctgcttttggtgtcttcggctgccaatatttctcttcggggaaatattactgggaagtagatgtgtctggaaagattg
cctggatcctgggcgtacacagtaaaataagtagtctgaataaaaggaagagctctgggtttgcttttgatccaagtgtaaattattc
aaaagtttactccagatatagacctcaatatggctactgggttataggattacagaatacatgtgaatataatgcttttgaggactcct
cctcttctgatcccaaggttttgactctctttatggctgtgcctccctgtcgtattggggttttcctagactatgaggcaggcattgtctc
atttttcaatgtcacaaaccacggagcactcatctacaagttctctggatgtcgcttttctcgacctgcttatccgtatttcaatccttgg
aactgcctagtccccatgactgtgtgcccaccgagctcctga
PROTEIN (498 aa)
MDFSVKVDIEKEVTCPICLELLTEPLSLDCGHSFCQACITAKIKESVIISRGESSCPV
CQTRFQPGNLRPNRHLANIVERVKEVKMSPQEGQKRDVCEHHGKKLQIFCKEDG
KVICWVCELSQEHQGHQTFRINEVVKECQEKLQVALQRLIKEDQEAEKLEDDIR
QERTAWKNYIQIERQKILKGFNEMRVILDNEEQRELQKLEEGEVNVLDNLAAAT
DQLVQQRQDASTLISDLQRRLRGSSVEMLQDVIDVMKRSESWTLKKPKSVSKKL
KSVFRVPDLSGMLQVLKELTDVQYYWVDVMLNPGSATSNVAISVDQRQVKTVR
TCTFKNSNPCDFSAFGVFGCQYFSSGKYYWEVDVSGKIAWILGVHSKISSLNKRK
SSGFAFDPSVNYSKVYSRYRPQYGYWVIGLQNTCEYNAFEDSSSSDPKVLTLFM
AVPPCRIGVFLDYEAGIVSFFNVTNHGALIYKFSGCRFSRPAYPYFNPWNCLVPM
TVCPPSS
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Appendix 3: Ethics approval notice for use of human subjects.

(Contact information removed for publication)

(Signature removed for publication)

(Contact information removed for publication)
Contact
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